{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "d995c525",
   "metadata": {},
   "source": [
    "# IQVIA NLP - FDA Drug Label Biomarkers\n",
    "\n",
    "## API Description\n",
    "Understanding biomarkers for drug efficacy or disease progression is critical in clinical development. Relevant data is often in unstructured text, such as clinical trial records, and drug labels.   For Data Scientists, the FDA Drug Label Biomarkers API solves this problem by offering an API that extracts gene/protein biomarkers from specific regions of FDA Drug labels (Indications and Usages section). Biomarker-disease relationships are provided (e.g.positive, negative); diseases are mapped to MedDRA, and mechanism of action data are also extracted.\n",
    "\n",
    "## Accessing the API\n",
    "In order to consume this API, you will first need to Request access to the FDA Drug Label Biomarkers API \n",
    "via this link:\n",
    "https://api-marketplace.work.iqvia.com/s/communityapi/a085w00000ytJqMAAU/api-marketplaceiqvianlpfdadruglabelbiomarkerspreview .\n",
    "\n",
    "Please refer to \"API Documentation\" to learn more about accessing and using the API.\n",
    "\n",
    "## Notebook Description\n",
    "This notebook is designed to biomarkers and their related diseases from from openFDA drug product labeling records. Users could specify records of interest by supplying FDA Drug Label document identifiers in the 'FDAID' parameter when posting the request.\n",
    "\n",
    "### Authorization\n",
    "The instructions for getting your credentials and the API endpoint URL can be found under the section \"Get Started\" and \"How to use the API\" following this link: https://api-marketplace.work.iqvia.com/s/communityapi/a085w00000ytJqMAAU/api-marketplaceiqvianlpfdadruglabelbiomarkerspreview ."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "6043edcd",
   "metadata": {
    "pycharm": {
     "name": "#%%\n"
    }
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Marketplace clientId: 77922ba7e417474a959a705fee4f272f\n",
      "Marketplace clientSecret: ········\n",
      "Checking your credentials, please wait...\n",
      "Congratulations! Your credentials are accepted!\n"
     ]
    }
   ],
   "source": [
    "import getpass\n",
    "import requests\n",
    "\n",
    "# In this demo scenario, URL for US based customers\n",
    "# api_marketplace_url = 'https://vt.us-rds.solutions.iqvia.com/fda/api/v1/biomarkers'\n",
    "# In this demo scenario, URL for EU based customers\n",
    "api_marketplace_url = 'https://vt.eu-apim.solutions.iqvia.com/eu/fda/api/v1/biomarkers'\n",
    "\n",
    "mkp_user = input(\"Marketplace clientId: \")\n",
    "mkp_password = getpass.getpass(\"Marketplace clientSecret: \")\n",
    "mkp_headers = {'clientId': mkp_user, 'clientSecret': mkp_password}\n",
    "\n",
    "# Check credentials by making a dummy request\n",
    "print(\"Checking your credentials, please wait...\")\n",
    "response = requests.get(api_marketplace_url, headers=mkp_headers)\n",
    "\n",
    "if response.status_code == 200:\n",
    "    print(\"Congratulations! Your credentials are accepted!\")\n",
    "else:\n",
    "    raise Exception(f\"Error: {response}\")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "ad2293f4",
   "metadata": {},
   "source": [
    "### Example: Make a request for a list of known FDA Drug Label documents\n",
    "FDA Drug Label Biomarker NLP API expects openFDA application number (FDAID) as input parameter. This example shows how to make a request to the API with a list of FDAIDs.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "9cfca417",
   "metadata": {
    "pycharm": {
     "name": "#%%\n"
    }
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Posting request to extract biomarkers and related diseases from specified CT.gov documents...\n",
      "Processing NDA204114...\n",
      "Success!\n",
      "Processing ANDA076183...\n",
      "Success!\n",
      "[[{'Biomarker': 'ABCB1', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... , trametinib is not an inhibitor of P-gp, BCRP, OATP1B1, ...'}, {'Biomarker': 'ABCB1', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... , trametinib is not an inhibitor of P-gp, BCRP, OATP1B1, ...'}, {'Biomarker': 'ABCG2', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... , trametinib is not an inhibitor of P-gp, BCRP, OATP1B1, OATP1B3, ...'}, {'Biomarker': 'ABCG2', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... , trametinib is not an inhibitor of P-gp, BCRP, OATP1B1, OATP1B3, ...'}, {'Biomarker': 'ALK', 'Relation': 'no mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... or MEK inhibitor, and absence of EGFR mutation or ALK rearrangement (unless patients had ...'}, {'Biomarker': 'ALK', 'Relation': 'no mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... or MEK inhibitor, and absence of EGFR mutation or ALK rearrangement (unless patients had ...'}, {'Biomarker': 'ALK', 'Relation': 'rearrangement', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... absence of EGFR mutation or ALK rearrangement (unless patients had progression ...'}, {'Biomarker': 'ALK', 'Relation': 'rearrangement', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... absence of EGFR mutation or ALK rearrangement (unless patients had progression ...'}, {'Biomarker': 'BRAF', 'Relation': 'activation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... V600E mutations result in constitutive activation of the BRAF pathway which includes MEK1 and ...'}, {'Biomarker': 'BRAF', 'Relation': 'activation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... V600E mutations result in constitutive activation of the BRAF pathway which includes MEK1 and ...'}, {'Biomarker': 'BRAF', 'Relation': 'diagnostic', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... retrospectively using an FDA-approved companion diagnostic test, THxID ® -BRAF assay.'}, {'Biomarker': 'BRAF', 'Relation': 'diagnostic', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... retrospectively using an FDA-approved companion diagnostic test, THxID ® -BRAF assay.'}, {'Biomarker': 'BRAF', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... mechanism of intrinsic resistance to BRAF inhibitors [see Indications and Usage ...'}, {'Biomarker': 'BRAF', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... ; prior treatment with a BRAF inhibitor or MEK inhibitor was not ...'}, {'Biomarker': 'BRAF', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... ; prior treatment with a BRAF inhibitor or MEK inhibitor was not permitted.'}, {'Biomarker': 'BRAF', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... , no prior exposure to BRAF or MEK inhibitor, and absence of EGFR ...'}, {'Biomarker': 'BRAF', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... who received prior treatment with BRAF or MEK inhibitors; with symptomatic or untreated ...'}, {'Biomarker': 'BRAF', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... received prior treatment with a BRAF inhibitor.'}, {'Biomarker': 'BRAF', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... mechanism of intrinsic resistance to BRAF inhibitors [see Indications and Usage ...'}, {'Biomarker': 'BRAF', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... ; prior treatment with a BRAF inhibitor or MEK inhibitor was not ...'}, {'Biomarker': 'BRAF', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... ; prior treatment with a BRAF inhibitor or MEK inhibitor was not permitted.'}, {'Biomarker': 'BRAF', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... , no prior exposure to BRAF or MEK inhibitor, and absence of EGFR ...'}, {'Biomarker': 'BRAF', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... who received prior treatment with BRAF or MEK inhibitors; with symptomatic or untreated ...'}, {'Biomarker': 'BRAF', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... received prior treatment with a BRAF inhibitor.'}, {'Biomarker': 'BRAF', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'SPL Patient Package Insert', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... who already have received a BRAF inhibitor for treatment of their melanoma...'}, {'Biomarker': 'BRAF', 'Relation': 'level', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... than the ULN vs. ≤ ULN) and BRAF mutation subtype (V600E vs. ...'}, {'Biomarker': 'BRAF', 'Relation': 'level', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... than the ULN vs. ≤ ULN) and BRAF mutation subtype (V600E vs. ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10002240', '[PT] MedDRA': 'Anaplastic thyroid cancer', 'Section': 'Indications & Usage', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10025650', '[PT] MedDRA': 'Malignant melanoma', 'Section': 'Adverse Reaction', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Adjuvant Treatment of BRAF V600E or V600K Mutation-Positive Melanoma'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10025650', '[PT] MedDRA': 'Malignant melanoma', 'Section': 'Adverse Reaction', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... 435 patients with Stage III melanoma with BRAF V600E or V600K mutations following complete resection who received ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10025650', '[PT] MedDRA': 'Malignant melanoma', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... metastatic (Stage IV) BRAF V600E or V600K mutation-positive cutaneous melanoma.'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10025650', '[PT] MedDRA': 'Malignant melanoma', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... dabrafenib for the treatment of BRAF V600E or V600K mutation-positive melanoma, metastatic to the brain...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10025650', '[PT] MedDRA': 'Malignant melanoma', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Adjuvant Treatment of BRAF V600E or V600K Mutation-Positive Melanoma'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10025650', '[PT] MedDRA': 'Malignant melanoma', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... enrolled patients with Stage III melanoma with BRAF V600E or V600K mutations as detected by the THxID ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10025650', '[PT] MedDRA': 'Malignant melanoma', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Adjuvant Treatment of BRAF V600E or V600K Mutation-Positive Melanoma'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10025650', '[PT] MedDRA': 'Malignant melanoma', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10025650', '[PT] MedDRA': 'Malignant melanoma', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... tests for the detection of BRAF V600 mutations in melanoma is available at: http://www.fda.gov/CompanionDiagnostics ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10025650', '[PT] MedDRA': 'Malignant melanoma', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Adjuvant Treatment of BRAF V600E or V600K Mutation-Positive Melanoma'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10025650', '[PT] MedDRA': 'Malignant melanoma', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... 435 patients with Stage III melanoma with BRAF V600E or V600K mutations following complete resection who received ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10025650', '[PT] MedDRA': 'Malignant melanoma', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... metastatic (Stage IV) BRAF V600E or V600K mutation-positive cutaneous melanoma.'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10025650', '[PT] MedDRA': 'Malignant melanoma', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... dabrafenib for the treatment of BRAF V600E or V600K mutation-positive melanoma, metastatic to the brain...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10025650', '[PT] MedDRA': 'Malignant melanoma', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Adjuvant Treatment of BRAF V600E or V600K Mutation-Positive Melanoma'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10025650', '[PT] MedDRA': 'Malignant melanoma', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... enrolled patients with Stage III melanoma with BRAF V600E or V600K mutations as detected by the THxID ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10028980', '[PT] MedDRA': 'Neoplasm', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10028980', '[PT] MedDRA': 'Neoplasm', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... dabrafenib for the treatment of BRAF V600E mutation-positive unresectable or metastatic solid tumors were evaluated in Trials BRF117019...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10028980', '[PT] MedDRA': 'Neoplasm', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... in adult patients with selected tumors with the BRAF V600E mutation, including high grade glioma ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10028980', '[PT] MedDRA': 'Neoplasm', 'Section': 'Dosage & Administration', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Confirm the presence of BRAF V600E or V600K mutation in tumor specimens prior to initiation of ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10028980', '[PT] MedDRA': 'Neoplasm', 'Section': 'Dosage & Administration', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Confirm the presence of BRAF V600E mutation in tumor specimens prior to initiation of ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10028980', '[PT] MedDRA': 'Neoplasm', 'Section': 'Dosage & Administration', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Confirm the presence of BRAF V600E mutation in tumor specimens prior to initiation of ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10028980', '[PT] MedDRA': 'Neoplasm', 'Section': 'Dosage & Administration', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Confirm the presence of BRAF V600E mutation in tumor specimens prior to initiation of ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10028980', '[PT] MedDRA': 'Neoplasm', 'Section': 'Dosage & Administration', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... test for the detection of BRAF V600E mutation in solid tumors other than melanoma and NSCLC ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10028980', '[PT] MedDRA': 'Neoplasm', 'Section': 'Indications & Usage', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10028980', '[PT] MedDRA': 'Neoplasm', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10028980', '[PT] MedDRA': 'Neoplasm', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10028980', '[PT] MedDRA': 'Neoplasm', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Confirm the presence of BRAF V600E or V600K mutation in tumor specimens prior to initiation of ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10028980', '[PT] MedDRA': 'Neoplasm', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Confirm the presence of BRAF V600E mutation in tumor specimens prior to initiation of ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10028980', '[PT] MedDRA': 'Neoplasm', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Confirm the presence of BRAF V600E mutation in tumor specimens prior to initiation of ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10028980', '[PT] MedDRA': 'Neoplasm', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Confirm the presence of BRAF V600E mutation in tumor specimens prior to initiation of ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10028980', '[PT] MedDRA': 'Neoplasm', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... test for the detection of BRAF V600E mutation in solid tumors other than melanoma and NSCLC ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10028980', '[PT] MedDRA': 'Neoplasm', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10028980', '[PT] MedDRA': 'Neoplasm', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10028980', '[PT] MedDRA': 'Neoplasm', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... dabrafenib for the treatment of BRAF V600E mutation-positive unresectable or metastatic solid tumors were evaluated in Trials BRF117019...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10028980', '[PT] MedDRA': 'Neoplasm', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... in adult patients with selected tumors with the BRAF V600E mutation, including high grade glioma ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10028980', '[PT] MedDRA': 'Neoplasm', 'Section': 'Recent Major Change', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Indications and Usage, BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors ( 1.5 )'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10028980', '[PT] MedDRA': 'Neoplasm', 'Section': 'Use In Specific Population', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10028997', '[PT] MedDRA': 'Neoplasm malignant', 'Section': 'Adverse Reaction', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... study in adult patients with cancers with the BRAF V600E mutation (Study BRF117019).'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10028997', '[PT] MedDRA': 'Neoplasm malignant', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... ) in patients with rare cancers with the BRAF V600E mutation, including locally advanced, ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10028997', '[PT] MedDRA': 'Neoplasm malignant', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... study in adult patients with cancers with the BRAF V600E mutation (Study BRF117019).'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10028997', '[PT] MedDRA': 'Neoplasm malignant', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... ) in patients with rare cancers with the BRAF V600E mutation, including locally advanced, ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10061289', '[PT] MedDRA': 'Metastatic neoplasm', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... dabrafenib for the treatment of BRAF V600E mutation-positive unresectable or metastatic solid tumors were evaluated in ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10061289', '[PT] MedDRA': 'Metastatic neoplasm', 'Section': 'Indications & Usage', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10061289', '[PT] MedDRA': 'Metastatic neoplasm', 'Section': 'Indications & Usage', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10061289', '[PT] MedDRA': 'Metastatic neoplasm', 'Section': 'Indications & Usage', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10061289', '[PT] MedDRA': 'Metastatic neoplasm', 'Section': 'Indications & Usage', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'BRAF V600E Mutation-Positive Metastatic NSCLC'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10061289', '[PT] MedDRA': 'Metastatic neoplasm', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... dabrafenib for the treatment of BRAF V600E mutation-positive unresectable or metastatic solid tumors were evaluated in ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10061289', '[PT] MedDRA': 'Metastatic neoplasm', 'Section': 'Recent Major Change', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Indications and Usage, BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors ( 1.5 )'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10061873', '[PT] MedDRA': 'Non-small cell lung cancer', 'Section': 'Indications & Usage', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Adverse Reaction', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... open-label trial of patients with BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma who ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... ) in 322 patients with BRAF V600E or V600K mutation-positive, unresectable or metastatic melanoma...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Tumor tissue was evaluated for BRAF mutations at a central testing site ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'The distribution of BRAF V600 mutations was BRAF V600E (87%...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'The distribution of BRAF V600 mutations was BRAF V600E (87%), ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... vs. ≤ ULN) and BRAF mutation subtype (V600E vs. V600K...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Randomization was stratified by BRAF mutation status (V600E or V600K...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... unknown (1%); BRAF V600E mutation (91%), BRAF ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... mutation (91%), BRAF V600K mutation (9%); macroscopic ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... IIIB vs. IIIC – and BRAF V600 mutation type – V600E vs. V600K...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... patients with retrospectively centrally confirmed BRAF V600E mutation-positive NSCLC with the Oncomine ™ ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'BRAF V600E Mutation-Positive Locally Advanced or Metastatic Anaplastic ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... trial in 40 patients with BRAF V600E or V600K mutation-positive, unresectable or metastatic melanoma ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... , and the distribution of BRAF V600 mutations was V600E (83%)...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... based on local assessments of BRAF V600E mutation status; a central laboratory ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... a central laboratory confirmed the BRAF V600E mutation in 93 of 105 patients...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... that enrolled patients with a BRAF V600E mutation.'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'BRAF mutation status for enrollment was determined ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... dabrafenib in patients with a BRAF V600E mutation.'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... patients with LGG with a BRAF V600E mutation.'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'For patients with BRAF V600E mutant LGG and HGG in Parts ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'BRAF V600E Mutation-Positive Locally Advanced or Metastatic Anaplastic ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... tests for the detection of BRAF V600E mutations in NSCLC is available at...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... test for the detection of BRAF V600E mutation in ATC is not currently ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... open-label trial of patients with BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma who ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'BRAF V600E mutations result in constitutive activation of ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... ) in 322 patients with BRAF V600E or V600K mutation-positive, unresectable or metastatic melanoma...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Tumor tissue was evaluated for BRAF mutations at a central testing site ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'The distribution of BRAF V600 mutations was BRAF V600E (87%...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'The distribution of BRAF V600 mutations was BRAF V600E (87%), ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... vs. ≤ ULN) and BRAF mutation subtype (V600E vs. V600K...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Randomization was stratified by BRAF mutation status (V600E or V600K...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... unknown (1%); BRAF V600E mutation (91%), BRAF ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... mutation (91%), BRAF V600K mutation (9%); macroscopic ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... IIIB vs. IIIC – and BRAF V600 mutation type – V600E vs. V600K...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... patients with retrospectively centrally confirmed BRAF V600E mutation-positive NSCLC with the Oncomine ™ ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'BRAF V600E Mutation-Positive Locally Advanced or Metastatic Anaplastic ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... trial in 40 patients with BRAF V600E or V600K mutation-positive, unresectable or metastatic melanoma ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... , and the distribution of BRAF V600 mutations was V600E (83%)...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... based on local assessments of BRAF V600E mutation status; a central laboratory ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... a central laboratory confirmed the BRAF V600E mutation in 93 of 105 patients...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... that enrolled patients with a BRAF V600E mutation.'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'BRAF mutation status for enrollment was determined ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... dabrafenib in patients with a BRAF V600E mutation.'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... patients with LGG with a BRAF V600E mutation.'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'For patients with BRAF V600E mutant LGG and HGG in Parts ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10025650', '[PT] MedDRA': 'Malignant melanoma', 'Section': 'Dosage & Administration', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... tests for the detection of BRAF V600 mutations in melanoma is available at: http://www.fda.gov/CompanionDiagnostics ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10025650', '[PT] MedDRA': 'Malignant melanoma', 'Section': 'Indications & Usage', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10025650', '[PT] MedDRA': 'Malignant melanoma', 'Section': 'Indications & Usage', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Adjuvant Treatment of BRAF V600E or V600K Mutation-Positive Melanoma'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10027480', '[PT] MedDRA': 'Metastatic malignant melanoma', 'Section': 'Indications & Usage', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10027480', '[PT] MedDRA': 'Metastatic malignant melanoma', 'Section': 'Indications & Usage', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10027480', '[PT] MedDRA': 'Metastatic malignant melanoma', 'Section': 'Indications & Usage', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '10027480', '[PT] MedDRA': 'Metastatic malignant melanoma', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'BRAF V600E mutations result in constitutive activation of ...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Dosage & Administration', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... tests for the detection of BRAF V600E mutations in NSCLC is available at...'}, {'Biomarker': 'BRAF', 'Relation': 'mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Dosage & Administration', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... test for the detection of BRAF V600E mutation in ATC is not currently ...'}, {'Biomarker': 'BRAF', 'Relation': 'positive', '[NID] MedDRA': '10025650', '[PT] MedDRA': 'Malignant melanoma', 'Section': 'Adverse Reaction', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Adjuvant Treatment of BRAF V600E or V600K Mutation-Positive Melanoma'}, {'Biomarker': 'BRAF', 'Relation': 'positive', '[NID] MedDRA': '10025650', '[PT] MedDRA': 'Malignant melanoma', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... metastatic (Stage IV) BRAF V600E or V600K mutation-positive cutaneous melanoma.'}, {'Biomarker': 'BRAF', 'Relation': 'positive', '[NID] MedDRA': '10025650', '[PT] MedDRA': 'Malignant melanoma', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... dabrafenib for the treatment of BRAF V600E or V600K mutation-positive melanoma, metastatic to the brain...'}, {'Biomarker': 'BRAF', 'Relation': 'positive', '[NID] MedDRA': '10025650', '[PT] MedDRA': 'Malignant melanoma', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Adjuvant Treatment of BRAF V600E or V600K Mutation-Positive Melanoma'}, {'Biomarker': 'BRAF', 'Relation': 'positive', '[NID] MedDRA': '10025650', '[PT] MedDRA': 'Malignant melanoma', 'Section': 'Indications & Usage', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Adjuvant Treatment of BRAF V600E or V600K Mutation-Positive Melanoma'}, {'Biomarker': 'BRAF', 'Relation': 'positive', '[NID] MedDRA': '10025650', '[PT] MedDRA': 'Malignant melanoma', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Adjuvant Treatment of BRAF V600E or V600K Mutation-Positive Melanoma'}, {'Biomarker': 'BRAF', 'Relation': 'positive', '[NID] MedDRA': '10025650', '[PT] MedDRA': 'Malignant melanoma', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Adjuvant Treatment of BRAF V600E or V600K Mutation-Positive Melanoma'}, {'Biomarker': 'BRAF', 'Relation': 'positive', '[NID] MedDRA': '10025650', '[PT] MedDRA': 'Malignant melanoma', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... metastatic (Stage IV) BRAF V600E or V600K mutation-positive cutaneous melanoma.'}, {'Biomarker': 'BRAF', 'Relation': 'positive', '[NID] MedDRA': '10025650', '[PT] MedDRA': 'Malignant melanoma', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... dabrafenib for the treatment of BRAF V600E or V600K mutation-positive melanoma, metastatic to the brain...'}, {'Biomarker': 'BRAF', 'Relation': 'positive', '[NID] MedDRA': '10025650', '[PT] MedDRA': 'Malignant melanoma', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Adjuvant Treatment of BRAF V600E or V600K Mutation-Positive Melanoma'}, {'Biomarker': 'BRAF', 'Relation': 'positive', '[NID] MedDRA': '10027480', '[PT] MedDRA': 'Metastatic malignant melanoma', 'Section': 'Indications & Usage', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma'}, {'Biomarker': 'BRAF', 'Relation': 'positive', '[NID] MedDRA': '10028980', '[PT] MedDRA': 'Neoplasm', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors'}, {'Biomarker': 'BRAF', 'Relation': 'positive', '[NID] MedDRA': '10028980', '[PT] MedDRA': 'Neoplasm', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... dabrafenib for the treatment of BRAF V600E mutation-positive unresectable or metastatic solid tumors were evaluated in Trials BRF117019...'}, {'Biomarker': 'BRAF', 'Relation': 'positive', '[NID] MedDRA': '10028980', '[PT] MedDRA': 'Neoplasm', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors'}, {'Biomarker': 'BRAF', 'Relation': 'positive', '[NID] MedDRA': '10028980', '[PT] MedDRA': 'Neoplasm', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors'}, {'Biomarker': 'BRAF', 'Relation': 'positive', '[NID] MedDRA': '10028980', '[PT] MedDRA': 'Neoplasm', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors'}, {'Biomarker': 'BRAF', 'Relation': 'positive', '[NID] MedDRA': '10028980', '[PT] MedDRA': 'Neoplasm', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... dabrafenib for the treatment of BRAF V600E mutation-positive unresectable or metastatic solid tumors were evaluated in Trials BRF117019...'}, {'Biomarker': 'BRAF', 'Relation': 'positive', '[NID] MedDRA': '10028980', '[PT] MedDRA': 'Neoplasm', 'Section': 'Recent Major Change', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Indications and Usage, BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors ( 1.5 )'}, {'Biomarker': 'BRAF', 'Relation': 'positive', '[NID] MedDRA': '10028980', '[PT] MedDRA': 'Neoplasm', 'Section': 'Use In Specific Population', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors'}, {'Biomarker': 'BRAF', 'Relation': 'positive', '[NID] MedDRA': '10061289', '[PT] MedDRA': 'Metastatic neoplasm', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... dabrafenib for the treatment of BRAF V600E mutation-positive unresectable or metastatic solid tumors were evaluated in ...'}, {'Biomarker': 'BRAF', 'Relation': 'positive', '[NID] MedDRA': '10061289', '[PT] MedDRA': 'Metastatic neoplasm', 'Section': 'Indications & Usage', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'BRAF V600E Mutation-Positive Metastatic NSCLC'}, {'Biomarker': 'BRAF', 'Relation': 'positive', '[NID] MedDRA': '10061289', '[PT] MedDRA': 'Metastatic neoplasm', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... dabrafenib for the treatment of BRAF V600E mutation-positive unresectable or metastatic solid tumors were evaluated in ...'}, {'Biomarker': 'BRAF', 'Relation': 'positive', '[NID] MedDRA': '10061289', '[PT] MedDRA': 'Metastatic neoplasm', 'Section': 'Recent Major Change', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Indications and Usage, BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors ( 1.5 )'}, {'Biomarker': 'BRAF', 'Relation': 'positive', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Adverse Reaction', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... open-label trial of patients with BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma who ...'}, {'Biomarker': 'BRAF', 'Relation': 'positive', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma'}, {'Biomarker': 'BRAF', 'Relation': 'positive', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... ) in 322 patients with BRAF V600E or V600K mutation-positive, unresectable or metastatic melanoma...'}, {'Biomarker': 'BRAF', 'Relation': 'positive', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... patients with retrospectively centrally confirmed BRAF V600E mutation-positive NSCLC with the Oncomine ™ ...'}, {'Biomarker': 'BRAF', 'Relation': 'positive', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'BRAF V600E Mutation-Positive Locally Advanced or Metastatic Anaplastic ...'}, {'Biomarker': 'BRAF', 'Relation': 'positive', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... trial in 40 patients with BRAF V600E or V600K mutation-positive, unresectable or metastatic melanoma ...'}, {'Biomarker': 'BRAF', 'Relation': 'positive', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma'}, {'Biomarker': 'BRAF', 'Relation': 'positive', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'BRAF V600E Mutation-Positive Locally Advanced or Metastatic Anaplastic ...'}, {'Biomarker': 'BRAF', 'Relation': 'positive', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... open-label trial of patients with BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma who ...'}, {'Biomarker': 'BRAF', 'Relation': 'positive', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma'}, {'Biomarker': 'BRAF', 'Relation': 'positive', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... ) in 322 patients with BRAF V600E or V600K mutation-positive, unresectable or metastatic melanoma...'}, {'Biomarker': 'BRAF', 'Relation': 'positive', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... patients with retrospectively centrally confirmed BRAF V600E mutation-positive NSCLC with the Oncomine ™ ...'}, {'Biomarker': 'BRAF', 'Relation': 'positive', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'BRAF V600E Mutation-Positive Locally Advanced or Metastatic Anaplastic ...'}, {'Biomarker': 'BRAF', 'Relation': 'positive', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... trial in 40 patients with BRAF V600E or V600K mutation-positive, unresectable or metastatic melanoma ...'}, {'Biomarker': 'CYP1A2', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... , but is not an inhibitor of CYP1A2, CYP2A6, CYP2B6, ...'}, {'Biomarker': 'CYP1A2', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... , but is not an inhibitor of CYP1A2, CYP2A6, CYP2B6, ...'}, {'Biomarker': 'CYP2A6', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... , but is not an inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C9, ...'}, {'Biomarker': 'CYP2A6', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... , but is not an inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C9, ...'}, {'Biomarker': 'CYP2B6', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... , but is not an inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, ...'}, {'Biomarker': 'CYP2B6', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... , but is not an inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, ...'}, {'Biomarker': 'CYP2C8', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... studies, trametinib is an inhibitor of CYP2C8, but is not an ...'}, {'Biomarker': 'CYP2C8', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... studies, trametinib is an inhibitor of CYP2C8, but is not an ...'}, {'Biomarker': 'CYP2C9', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... , but is not an inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, ...'}, {'Biomarker': 'CYP2C9', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... , but is not an inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, ...'}, {'Biomarker': 'CYP2C19', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... , but is not an inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 ...'}, {'Biomarker': 'CYP2C19', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... , but is not an inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 ...'}, {'Biomarker': 'CYP3A4', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Trametinib is an inducer of CYP3A in vitro .'}, {'Biomarker': 'CYP3A4', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Trametinib is an inducer of CYP3A in vitro .'}, {'Biomarker': 'EPHB2', 'Relation': 'phosphorylation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... biomarkers, including inhibition of phosphorylated ERK, inhibition of Ki67 (...'}, {'Biomarker': 'EPHB2', 'Relation': 'phosphorylation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... biomarkers, including inhibition of phosphorylated ERK, inhibition of Ki67 (...'}, {'Biomarker': 'GOT1', 'Relation': 'increase', '[NID] MedDRA': '10020635', '[PT] MedDRA': 'Hyperglycaemia', 'Section': 'Adverse Reaction', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... lymphopenia, increased ALT, increased AST, hyperglycemia (each n = 1...'}, {'Biomarker': 'GOT1', 'Relation': 'increase', '[NID] MedDRA': '10020635', '[PT] MedDRA': 'Hyperglycaemia', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... lymphopenia, increased ALT, increased AST, hyperglycemia (each n = 1...'}, {'Biomarker': 'GOT1', 'Relation': 'increase', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Adverse Reaction', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... ), increased ALT and increased AST (each n = 3...'}, {'Biomarker': 'GOT1', 'Relation': 'increase', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Adverse Reaction', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... , increased ALT, and increased AST (each n = 1...'}, {'Biomarker': 'GOT1', 'Relation': 'increase', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Adverse Reaction', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Increased AST'}, {'Biomarker': 'GOT1', 'Relation': 'increase', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Adverse Reaction', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Increased AST'}, {'Biomarker': 'GOT1', 'Relation': 'increase', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Adverse Reaction', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Increased AST'}, {'Biomarker': 'GOT1', 'Relation': 'increase', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Adverse Reaction', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Increased AST'}, {'Biomarker': 'GOT1', 'Relation': 'increase', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Adverse Reaction', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... increased (6%), AST increased (4.2%) and ejection ...'}, {'Biomarker': 'GOT1', 'Relation': 'increase', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Adverse Reaction', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Increased AST'}, {'Biomarker': 'GOT1', 'Relation': 'increase', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... ), increased ALT and increased AST (each n = 3...'}, {'Biomarker': 'GOT1', 'Relation': 'increase', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... , increased ALT, and increased AST (each n = 1...'}, {'Biomarker': 'GOT1', 'Relation': 'increase', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Increased AST'}, {'Biomarker': 'GOT1', 'Relation': 'increase', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Increased AST'}, {'Biomarker': 'GOT1', 'Relation': 'increase', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Increased AST'}, {'Biomarker': 'GOT1', 'Relation': 'increase', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Increased AST'}, {'Biomarker': 'GOT1', 'Relation': 'increase', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... increased (6%), AST increased (4.2%) and ejection ...'}, {'Biomarker': 'GOT1', 'Relation': 'increase', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Increased AST'}, {'Biomarker': 'GOT1', 'Relation': 'level', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... impairment defined by bilirubin and AST levels, mild, moderate, ...'}, {'Biomarker': 'GOT1', 'Relation': 'level', '[NID] MedDRA': '10019670', '[PT] MedDRA': 'Hepatic function abnormal', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... bilirubin > 1x to 1.5x ULN and any AST) hepatic impairment.'}, {'Biomarker': 'GOT1', 'Relation': 'level', '[NID] MedDRA': '10019670', '[PT] MedDRA': 'Hepatic function abnormal', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... bilirubin > 3x to 10x ULN and any AST) hepatic impairment.'}, {'Biomarker': 'GOT1', 'Relation': 'level', '[NID] MedDRA': '10019670', '[PT] MedDRA': 'Hepatic function abnormal', 'Section': 'Use In Specific Population', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... bilirubin > 1x to 1.5x ULN and any AST) hepatic impairment.'}, {'Biomarker': 'GOT1', 'Relation': 'level', '[NID] MedDRA': '10019670', '[PT] MedDRA': 'Hepatic function abnormal', 'Section': 'Use In Specific Population', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... bilirubin > 3x to 10x ULN and any AST) hepatic impairment.'}, {'Biomarker': 'GOT1', 'Relation': 'level', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... ) and aspartate aminotransferase (AST) > ULN or bilirubin > 1x ...'}, {'Biomarker': 'GOT1', 'Relation': 'level', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... bilirubin > 1.5x to 3x ULN and any AST) or severe (bilirubin ...'}, {'Biomarker': 'GOT1', 'Relation': 'level', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... impairment defined by bilirubin and AST levels, mild, moderate, ...'}, {'Biomarker': 'GOT1', 'Relation': 'level', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Use In Specific Population', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... ) and aspartate aminotransferase (AST) > ULN or bilirubin > 1x ...'}, {'Biomarker': 'GOT1', 'Relation': 'level', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Use In Specific Population', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... bilirubin > 1.5x to 3x ULN and any AST) or severe (bilirubin ...'}, {'Biomarker': 'GPT', 'Relation': 'increase', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Adverse Reaction', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Increased alanine aminotransferase (ALT)'}, {'Biomarker': 'GPT', 'Relation': 'increase', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Adverse Reaction', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... n = 4), increased ALT and increased AST (each ...'}, {'Biomarker': 'GPT', 'Relation': 'increase', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Adverse Reaction', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... neutropenia, thrombocytopenia, increased ALT, and increased AST (each n = ...'}, {'Biomarker': 'GPT', 'Relation': 'increase', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Adverse Reaction', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Increased ALT'}, {'Biomarker': 'GPT', 'Relation': 'increase', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Adverse Reaction', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Increased ALT'}, {'Biomarker': 'GPT', 'Relation': 'increase', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Adverse Reaction', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Increased ALT'}, {'Biomarker': 'GPT', 'Relation': 'increase', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Adverse Reaction', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Increased ALT'}, {'Biomarker': 'GPT', 'Relation': 'increase', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Adverse Reaction', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... > 3% of patients included ALT increased (6%), AST ...'}, {'Biomarker': 'GPT', 'Relation': 'increase', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Adverse Reaction', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Increased ALT'}, {'Biomarker': 'GPT', 'Relation': 'increase', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Increased alanine aminotransferase (ALT)'}, {'Biomarker': 'GPT', 'Relation': 'increase', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... n = 4), increased ALT and increased AST (each ...'}, {'Biomarker': 'GPT', 'Relation': 'increase', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... neutropenia, thrombocytopenia, increased ALT, and increased AST (each n = ...'}, {'Biomarker': 'GPT', 'Relation': 'increase', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Increased ALT'}, {'Biomarker': 'GPT', 'Relation': 'increase', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Increased ALT'}, {'Biomarker': 'GPT', 'Relation': 'increase', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Increased ALT'}, {'Biomarker': 'GPT', 'Relation': 'increase', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Increased ALT'}, {'Biomarker': 'GPT', 'Relation': 'increase', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... > 3% of patients included ALT increased (6%), AST ...'}, {'Biomarker': 'GPT', 'Relation': 'increase', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Increased ALT'}, {'Biomarker': 'KCNK3', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... , trametinib is not an inhibitor of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, OAT3, OCT2, ...'}, {'Biomarker': 'KCNK3', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... , trametinib is not an inhibitor of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, OAT3, OCT2, ...'}, {'Biomarker': 'MAP2K1', 'Relation': 'activation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... (MEK1) and MEK2 activation and of MEK1 and MEK2 kinase activity.'}, {'Biomarker': 'MAP2K1', 'Relation': 'activation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... (MEK1) and MEK2 activation and of MEK1 and MEK2 kinase activity.'}, {'Biomarker': 'MAP2K2', 'Relation': 'activation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... 1 (MEK1) and MEK2 activation and of MEK1 and MEK2 ...'}, {'Biomarker': 'MAP2K2', 'Relation': 'activation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... 1 (MEK1) and MEK2 activation and of MEK1 and MEK2 ...'}, {'Biomarker': 'MAP2K7', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... with a BRAF inhibitor or MEK inhibitor was not permitted.'}, {'Biomarker': 'MAP2K7', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... prior exposure to BRAF or MEK inhibitor, and absence of EGFR ...'}, {'Biomarker': 'MAP2K7', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... prior treatment with BRAF or MEK inhibitors; with symptomatic or untreated ...'}, {'Biomarker': 'MAP2K7', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... with a BRAF inhibitor or MEK inhibitor was not permitted.'}, {'Biomarker': 'MAP2K7', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... prior exposure to BRAF or MEK inhibitor, and absence of EGFR ...'}, {'Biomarker': 'MAP2K7', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... prior treatment with BRAF or MEK inhibitors; with symptomatic or untreated ...'}, {'Biomarker': 'MAP2K7', 'Relation': 'no mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Study', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... prior exposure to BRAF or MEK inhibitor, and absence of EGFR mutation or ALK rearrangement (unless ...'}, {'Biomarker': 'MAP2K7', 'Relation': 'no mutation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... prior exposure to BRAF or MEK inhibitor, and absence of EGFR mutation or ALK rearrangement (unless ...'}, {'Biomarker': 'MAPK1', 'Relation': 'phosphorylation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... biomarkers, including inhibition of phosphorylated ERK, inhibition of Ki67 (...'}, {'Biomarker': 'MAPK1', 'Relation': 'phosphorylation', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... biomarkers, including inhibition of phosphorylated ERK, inhibition of Ki67 (...'}, {'Biomarker': 'MAPK3', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Trametinib is a reversible inhibitor of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 ...'}, {'Biomarker': 'MAPK3', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': 'Trametinib is a reversible inhibitor of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 ...'}, {'Biomarker': 'PAK2', 'Relation': 'increase', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... cell proliferation), and increases in p27 (a marker of apoptosis...'}, {'Biomarker': 'PAK2', 'Relation': 'increase', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... cell proliferation), and increases in p27 (a marker of apoptosis...'}, {'Biomarker': 'SLC22A6', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... , trametinib is not an inhibitor of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, OAT3, OCT2, ...'}, {'Biomarker': 'SLC22A6', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... , trametinib is not an inhibitor of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, OAT3, OCT2, ...'}, {'Biomarker': 'SLCO1B1', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... , trametinib is not an inhibitor of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, ...'}, {'Biomarker': 'SLCO1B1', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... , trametinib is not an inhibitor of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, ...'}, {'Biomarker': 'SLCO1B3', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... , trametinib is not an inhibitor of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, OAT3, ...'}, {'Biomarker': 'SLCO1B3', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'NDA204114', 'Label Revision Date': '20220622', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1', 'Hit': '... , trametinib is not an inhibitor of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, OAT3, ...'}], [{'Biomarker': 'CYP3A4', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211006', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cdb2c4b4-a20a-3f8f-e053-2a95a90aaf72', 'Hit': 'CYP 3A4 Inducers: Ondansetron elimination may be ...'}, {'Biomarker': 'CYP3A4', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211006', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cdb2c4b4-a20a-3f8f-e053-2a95a90aaf72', 'Hit': '... epileptic patients maintained chronically on CYP3A4 inducers, carbamazepine, or phenytoin...'}, {'Biomarker': 'CYP3A4', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Drug Interaction', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211006', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cdb2c4b4-a20a-3f8f-e053-2a95a90aaf72', 'Hit': 'In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, ...'}, {'Biomarker': 'CYP4F3', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211006', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cdb2c4b4-a20a-3f8f-e053-2a95a90aaf72', 'Hit': '... elimination may be affected by cytochrome P-450 inducers.'}, {'Biomarker': 'CYP4F3', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Drug Interaction', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211006', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cdb2c4b4-a20a-3f8f-e053-2a95a90aaf72', 'Hit': '... itself appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the ...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '10020751', '[PT] MedDRA': 'Hypersensitivity', 'Section': 'Warning And Precaution', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211006', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cdb2c4b4-a20a-3f8f-e053-2a95a90aaf72', 'Hit': '... in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '10040108', '[PT] MedDRA': 'Serotonin syndrome', 'Section': 'Warning And Precaution', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211006', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cdb2c4b4-a20a-3f8f-e053-2a95a90aaf72', 'Hit': 'The majority of reports of serotonin syndrome related to 5-HT3 receptor antagonist use occurred in a post-anesthesia ...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Drug Interaction', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211006', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cdb2c4b4-a20a-3f8f-e053-2a95a90aaf72', 'Hit': '... following the concomitant use of 5-HT3 receptor antagonists and other serotonergic drugs, ...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'SPL Unclassified', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211006', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cdb2c4b4-a20a-3f8f-e053-2a95a90aaf72', 'Hit': 'Ondansetron tablets are 5-HT3 receptor antagonist indicated for the prevention of...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'SPL Unclassified', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211006', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cdb2c4b4-a20a-3f8f-e053-2a95a90aaf72', 'Hit': 'Serotonin syndrome: Reported with 5-HT3 receptor antagonists alone but particularly with concomitant ...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Warning And Precaution', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211006', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cdb2c4b4-a20a-3f8f-e053-2a95a90aaf72', 'Hit': '... syndrome has been reported with 5-HT3 receptor antagonists alone.'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Warning And Precaution', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211006', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cdb2c4b4-a20a-3f8f-e053-2a95a90aaf72', 'Hit': '... of serotonin syndrome related to 5-HT3 receptor antagonist use occurred in a post-anesthesia ...'}, {'Biomarker': 'HTR3A', 'Relation': 'blocker', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Description', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211006', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cdb2c4b4-a20a-3f8f-e053-2a95a90aaf72', 'Hit': '... of ondansetron and a selective blocking agent of the serotonin 5-HT3 receptor type.'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10028997', '[PT] MedDRA': 'Neoplasm malignant', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211006', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cdb2c4b4-a20a-3f8f-e053-2a95a90aaf72', 'Hit': 'highly emetogenic cancer chemotherapy, including cisplatin greater ...'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10028997', '[PT] MedDRA': 'Neoplasm malignant', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211006', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cdb2c4b4-a20a-3f8f-e053-2a95a90aaf72', 'Hit': '... repeat courses of moderately emetogenic cancer chemotherapy.'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10047700', '[PT] MedDRA': 'Vomiting', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211006', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cdb2c4b4-a20a-3f8f-e053-2a95a90aaf72', 'Hit': '... indicated for the prevention of nausea and vomiting associated with:'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10066962', '[PT] MedDRA': 'Procedural nausea', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211006', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cdb2c4b4-a20a-3f8f-e053-2a95a90aaf72', 'Hit': '... indicated for the prevention of postoperative nausea and/or vomiting.'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10066963', '[PT] MedDRA': 'Procedural vomiting', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211006', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cdb2c4b4-a20a-3f8f-e053-2a95a90aaf72', 'Hit': '... postoperative nausea and/or vomiting.'}, {'Biomarker': 'CYP2D6', 'Relation': 'deficient', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': '... one enzyme (e.g., CYP2D6 genetic deficiency) will be compensated by ...'}, {'Biomarker': 'CYP2D6', 'Relation': 'deficient', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': '... one enzyme (e.g., CYP2D6 genetic deficiency) will be compensated by ...'}, {'Biomarker': 'CYP2D7', 'Relation': 'deficient', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': '... one enzyme (e.g., CYP2D6 genetic deficiency) will be compensated by ...'}, {'Biomarker': 'CYP2D7', 'Relation': 'deficient', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': '... one enzyme (e.g., CYP2D6 genetic deficiency) will be compensated by ...'}, {'Biomarker': 'CYP3A4', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': '... epileptic patients maintained chronically on CYP3A4 inducers, carbamazepine, or phenytoin...'}, {'Biomarker': 'CYP3A4', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': '... epileptic patients maintained chronically on CYP3A4 inducers, carbamazepine, or phenytoin...'}, {'Biomarker': 'CYP3A4', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': 'In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, ...'}, {'Biomarker': 'CYP3A4', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Precaution', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': 'In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, ...'}, {'Biomarker': 'CYP4F3', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': '... elimination may be affected by cytochrome P-450 inducers.'}, {'Biomarker': 'CYP4F3', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': '... elimination may be affected by cytochrome P-450 inducers.'}, {'Biomarker': 'CYP4F3', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': '... itself appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the ...'}, {'Biomarker': 'CYP4F3', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Precaution', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': '... itself appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the ...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '10020751', '[PT] MedDRA': 'Hypersensitivity', 'Section': 'Warning', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': '... in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '10040108', '[PT] MedDRA': 'Serotonin syndrome', 'Section': 'Warning', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': 'The majority of reports of serotonin syndrome related to 5-HT3 receptor antagonist use occurred in a post-anesthesia ...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': 'Ondansetron is a selective 5-HT3 receptor antagonist.'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': '... or pretreatment with a serotonin 5-HT3 receptor antagonist.'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': 'Ondansetron is a selective 5-HT3 receptor antagonist.'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': '... or pretreatment with a serotonin 5-HT3 receptor antagonist.'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': '... following the concomitant use of 5-HT3 receptor antagonists and other serotonergic drugs, ...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Precaution', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': '... following the concomitant use of 5-HT3 receptor antagonists and other serotonergic drugs, ...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Warning', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': '... syndrome has been reported with 5-HT3 receptor antagonists alone.'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Warning', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': '... of serotonin syndrome related to 5-HT3 receptor antagonist use occurred in a post-anesthesia ...'}, {'Biomarker': 'HTR3A', 'Relation': 'blocker', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Description', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': '... of ondansetron and a selective blocking agent of the serotonin 5-HT3 receptor type.'}, {'Biomarker': 'LOC107987479', 'Relation': 'deficient', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': '... one enzyme (e.g., CYP2D6 genetic deficiency) will be compensated by ...'}, {'Biomarker': 'LOC107987479', 'Relation': 'deficient', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': '... one enzyme (e.g., CYP2D6 genetic deficiency) will be compensated by ...'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10028813', '[PT] MedDRA': 'Nausea', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': '... there is little expectation that nausea and/or vomiting will ...'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10028813', '[PT] MedDRA': 'Nausea', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': 'In patients where nausea and/or vomiting must ...'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10028997', '[PT] MedDRA': 'Neoplasm malignant', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': '... vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin ≥...'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10028997', '[PT] MedDRA': 'Neoplasm malignant', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': '... repeat courses of moderately emetogenic cancer chemotherapy.'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10047700', '[PT] MedDRA': 'Vomiting', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': 'Prevention of nausea and vomiting associated with highly emetogenic cancer ...'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10047700', '[PT] MedDRA': 'Vomiting', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': 'Prevention of nausea and vomiting associated with initial and repeat ...'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10047700', '[PT] MedDRA': 'Vomiting', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': 'Prevention of nausea and vomiting associated with radiotherapy in patients ...'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10047700', '[PT] MedDRA': 'Vomiting', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': '... that nausea and/or vomiting will occur postoperatively.'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10047700', '[PT] MedDRA': 'Vomiting', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': '... where nausea and/or vomiting must be avoided postoperatively, ...'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10066962', '[PT] MedDRA': 'Procedural nausea', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': 'Prevention of postoperative nausea and/or vomiting.'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10066962', '[PT] MedDRA': 'Procedural nausea', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': '... even where the incidence of postoperative nausea and/or vomiting is ...'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10066963', '[PT] MedDRA': 'Procedural vomiting', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': '... postoperative nausea and/or vomiting.'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10066963', '[PT] MedDRA': 'Procedural vomiting', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20190429', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cb02f2d7-31a9-4f12-880e-7ce7d85440d4', 'Hit': '... postoperative nausea and/or vomiting is low.'}, {'Biomarker': 'CYP2D6', 'Relation': 'deficient', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': '... one enzyme (e.g., CYP2D6 genetic deficiency) will be compensated by ...'}, {'Biomarker': 'CYP2D6', 'Relation': 'deficient', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': '... one enzyme (e.g., CYP2D6 genetic deficiency) will be compensated by ...'}, {'Biomarker': 'CYP2D7', 'Relation': 'deficient', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': '... one enzyme (e.g., CYP2D6 genetic deficiency) will be compensated by ...'}, {'Biomarker': 'CYP2D7', 'Relation': 'deficient', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': '... one enzyme (e.g., CYP2D6 genetic deficiency) will be compensated by ...'}, {'Biomarker': 'CYP3A4', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': 'CYP 3A4 Inducers: Ondansetron elimination may be ...'}, {'Biomarker': 'CYP3A4', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': '... epileptic patients maintained chronically on CYP3A4 inducers, carbamazepine, or phenytoin...'}, {'Biomarker': 'CYP3A4', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Drug Interaction', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': 'In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, ...'}, {'Biomarker': 'CYP3A4', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': 'In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, ...'}, {'Biomarker': 'CYP3A4', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': 'CYP 3A4 Inducers: Ondansetron elimination may be ...'}, {'Biomarker': 'CYP3A4', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': '... epileptic patients maintained chronically on CYP3A4 inducers, carbamazepine, or phenytoin...'}, {'Biomarker': 'CYP4F3', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': '... elimination may be affected by cytochrome P-450 inducers.'}, {'Biomarker': 'CYP4F3', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': '... elimination may be affected by cytochrome P-450 inducers.'}, {'Biomarker': 'CYP4F3', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Drug Interaction', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': '... itself appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the ...'}, {'Biomarker': 'CYP4F3', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': '... itself appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the ...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '10020751', '[PT] MedDRA': 'Hypersensitivity', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': '... in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '10020751', '[PT] MedDRA': 'Hypersensitivity', 'Section': 'Warning And Precaution', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': '... in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '10040108', '[PT] MedDRA': 'Serotonin syndrome', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': 'The majority of reports of serotonin syndrome related to 5-HT3 receptor antagonist use occurred in a post-anesthesia ...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '10040108', '[PT] MedDRA': 'Serotonin syndrome', 'Section': 'Warning And Precaution', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': 'The majority of reports of serotonin syndrome related to 5-HT3 receptor antagonist use occurred in a post-anesthesia ...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': 'Ondansetron is a selective 5-HT3 receptor antagonist.'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Drug Interaction', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': '... following the concomitant use of 5-HT3 receptor antagonists and other serotonergic drugs, ...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': 'Ondansetron tablets are 5-HT3 receptor antagonist indicated for the prevention of...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': '... syndrome has been reported with 5-HT3 receptor antagonists alone.'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': '... of serotonin syndrome related to 5-HT3 receptor antagonist use occurred in a post-anesthesia ...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': '... following the concomitant use of 5-HT3 receptor antagonists and other serotonergic drugs, ...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': 'Ondansetron is a selective 5-HT3 receptor antagonist.'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Warning And Precaution', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': 'Serotonin Syndrome : Reported with 5-HT3 receptor antagonists alone but particularly with concomitant ...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Warning And Precaution', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': '... syndrome has been reported with 5-HT3 receptor antagonists alone.'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Warning And Precaution', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': '... of serotonin syndrome related to 5-HT3 receptor antagonist use occurred in a post-anesthesia ...'}, {'Biomarker': 'HTR3A', 'Relation': 'blocker', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Description', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': '... of ondansetron and a selective blocking agent of the serotonin 5-HT3 receptor type.'}, {'Biomarker': 'LOC107987479', 'Relation': 'deficient', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': '... one enzyme (e.g., CYP2D6 genetic deficiency) will be compensated by ...'}, {'Biomarker': 'LOC107987479', 'Relation': 'deficient', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': '... one enzyme (e.g., CYP2D6 genetic deficiency) will be compensated by ...'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10028997', '[PT] MedDRA': 'Neoplasm malignant', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': 'highly emetogenic cancer chemotherapy, including cisplatin greater ...'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10028997', '[PT] MedDRA': 'Neoplasm malignant', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': '... repeat courses of moderately emetogenic cancer chemotherapy.'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10028997', '[PT] MedDRA': 'Neoplasm malignant', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': '... vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater ...'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10028997', '[PT] MedDRA': 'Neoplasm malignant', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': '... repeat courses of moderately emetogenic cancer chemotherapy (1)'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10047700', '[PT] MedDRA': 'Vomiting', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': '... indicated for the prevention of nausea and vomiting associated with:'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10047700', '[PT] MedDRA': 'Vomiting', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': 'nausea and vomiting associated with highly emetogenic cancer ...'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10047700', '[PT] MedDRA': 'Vomiting', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': 'nausea and vomiting associated with initial and repeat ...'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10047700', '[PT] MedDRA': 'Vomiting', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': 'nausea and vomiting associated with radiotherapy in patients ...'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10066962', '[PT] MedDRA': 'Procedural nausea', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': '... indicated for the prevention of postoperative nausea and/or vomiting.'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10066962', '[PT] MedDRA': 'Procedural nausea', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': 'postoperative nausea and/or vomiting (...'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10066963', '[PT] MedDRA': 'Procedural vomiting', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': '... postoperative nausea and/or vomiting.'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10066963', '[PT] MedDRA': 'Procedural vomiting', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20220503', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a29b5c18-9884-4c88-8827-65d9ad5f69f6', 'Hit': 'postoperative nausea and/or vomiting (1)'}, {'Biomarker': 'CYP2D6', 'Relation': 'deficient', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': '... one enzyme (e.g., CYP2D6 genetic deficiency) will be compensated by ...'}, {'Biomarker': 'CYP2D6', 'Relation': 'deficient', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': '... one enzyme (e.g., CYP2D6 genetic deficiency) will be compensated by ...'}, {'Biomarker': 'CYP2D7', 'Relation': 'deficient', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': '... one enzyme (e.g., CYP2D6 genetic deficiency) will be compensated by ...'}, {'Biomarker': 'CYP2D7', 'Relation': 'deficient', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': '... one enzyme (e.g., CYP2D6 genetic deficiency) will be compensated by ...'}, {'Biomarker': 'CYP3A4', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': 'CYP 3A4 Inducers: Ondansetron elimination may be ...'}, {'Biomarker': 'CYP3A4', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': '... epileptic patients maintained chronically on CYP3A4 inducers, carbamazepine, or phenytoin...'}, {'Biomarker': 'CYP3A4', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Drug Interaction', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': 'In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, ...'}, {'Biomarker': 'CYP3A4', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': 'In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, ...'}, {'Biomarker': 'CYP3A4', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': 'CYP 3A4 Inducers: Ondansetron elimination may be ...'}, {'Biomarker': 'CYP3A4', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': '... epileptic patients maintained chronically on CYP3A4 inducers, carbamazepine, or phenytoin...'}, {'Biomarker': 'CYP4F3', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': '... elimination may be affected by cytochrome P-450 inducers.'}, {'Biomarker': 'CYP4F3', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': '... elimination may be affected by cytochrome P-450 inducers.'}, {'Biomarker': 'CYP4F3', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Drug Interaction', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': '... itself appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the ...'}, {'Biomarker': 'CYP4F3', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': '... itself appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the ...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '10020751', '[PT] MedDRA': 'Hypersensitivity', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': '... in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '10020751', '[PT] MedDRA': 'Hypersensitivity', 'Section': 'Warning And Precaution', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': '... in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '10040108', '[PT] MedDRA': 'Serotonin syndrome', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': 'The majority of reports of serotonin syndrome related to 5-HT3 receptor antagonist use occurred in a post-anesthesia ...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '10040108', '[PT] MedDRA': 'Serotonin syndrome', 'Section': 'Warning And Precaution', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': 'The majority of reports of serotonin syndrome related to 5-HT3 receptor antagonist use occurred in a post-anesthesia ...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': 'Ondansetron is a selective 5-HT3 receptor antagonist.'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Drug Interaction', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': '... following the concomitant use of 5-HT3 receptor antagonists and other serotonergic drugs,including SSRIs ...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': 'Ondansetron tablets are 5-HT3 receptor antagonist indicated for the prevention of...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': '... syndrome has been reported with 5-HT3 receptor antagonists alone.'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': '... of serotonin syndrome related to 5-HT3 receptor antagonist use occurred in a post-anesthesia ...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': '... following the concomitant use of 5-HT3 receptor antagonists and other serotonergic drugs,including SSRIs ...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': 'Ondansetron is a selective 5-HT3 receptor antagonist.'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Warning And Precaution', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': 'Serotonin Syndrome : Reported with 5-HT3 receptor antagonists alone but particularly with concomitant ...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Warning And Precaution', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': '... syndrome has been reported with 5-HT3 receptor antagonists alone.'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Warning And Precaution', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': '... of serotonin syndrome related to 5-HT3 receptor antagonist use occurred in a post-anesthesia ...'}, {'Biomarker': 'HTR3A', 'Relation': 'blocker', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Description', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': '... of ondansetron and a selective blocking agent of the serotonin 5-HT3 receptor type.'}, {'Biomarker': 'LOC107987479', 'Relation': 'deficient', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': '... one enzyme (e.g., CYP2D6 genetic deficiency) will be compensated by ...'}, {'Biomarker': 'LOC107987479', 'Relation': 'deficient', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': '... one enzyme (e.g., CYP2D6 genetic deficiency) will be compensated by ...'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10028997', '[PT] MedDRA': 'Neoplasm malignant', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': 'highly emetogenic cancer chemotherapy, including cisplatin greater ...'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10028997', '[PT] MedDRA': 'Neoplasm malignant', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': '... repeat courses of moderately emetogenic cancer chemotherapy.'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10028997', '[PT] MedDRA': 'Neoplasm malignant', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': '... vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater ...'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10028997', '[PT] MedDRA': 'Neoplasm malignant', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': '... repeat courses of moderately emetogenic cancer chemotherapy (1)'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10047700', '[PT] MedDRA': 'Vomiting', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': '... indicated for the prevention of nausea and vomiting associated with:'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10047700', '[PT] MedDRA': 'Vomiting', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': 'nausea and vomiting associated with highly emetogenic cancer ...'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10047700', '[PT] MedDRA': 'Vomiting', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': 'nausea and vomiting associated with initial and repeat ...'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10047700', '[PT] MedDRA': 'Vomiting', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': 'nausea and vomiting associated with radiotherapy in patients ...'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10066962', '[PT] MedDRA': 'Procedural nausea', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': '... indicated for the prevention of postoperative nausea and/or vomiting.'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10066962', '[PT] MedDRA': 'Procedural nausea', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': 'postoperative nausea and/or vomiting (...'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10066963', '[PT] MedDRA': 'Procedural vomiting', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': '... postoperative nausea and/or vomiting.'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10066963', '[PT] MedDRA': 'Procedural vomiting', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20210525', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=476e704c-95ae-4591-94f7-ee4ab827ff13', 'Hit': 'postoperative nausea and/or vomiting (1)'}, {'Biomarker': 'CYP2D6', 'Relation': 'deficient', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': '... one enzyme (e.g., CYP2D6 genetic deficiency) will be compensated by ...'}, {'Biomarker': 'CYP2D6', 'Relation': 'deficient', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': '... one enzyme (e.g., CYP2D6 genetic deficiency) will be compensated by ...'}, {'Biomarker': 'CYP2D7', 'Relation': 'deficient', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': '... one enzyme (e.g., CYP2D6 genetic deficiency) will be compensated by ...'}, {'Biomarker': 'CYP2D7', 'Relation': 'deficient', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': '... one enzyme (e.g., CYP2D6 genetic deficiency) will be compensated by ...'}, {'Biomarker': 'CYP3A4', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': 'CYP 3A4 Inducers: Ondansetron elimination may be ...'}, {'Biomarker': 'CYP3A4', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': '... epileptic patients maintained chronically on CYP3A4 inducers, carbamazepine, or phenytoin...'}, {'Biomarker': 'CYP3A4', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Drug Interaction', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': 'In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, ...'}, {'Biomarker': 'CYP3A4', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': 'In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, ...'}, {'Biomarker': 'CYP3A4', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': 'CYP 3A4 Inducers: Ondansetron elimination may be ...'}, {'Biomarker': 'CYP3A4', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': '... epileptic patients maintained chronically on CYP3A4 inducers, carbamazepine, or phenytoin...'}, {'Biomarker': 'CYP4F3', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': '... elimination may be affected by cytochrome P-450 inducers.'}, {'Biomarker': 'CYP4F3', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': '... elimination may be affected by cytochrome P-450 inducers.'}, {'Biomarker': 'CYP4F3', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Drug Interaction', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': '... itself appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the ...'}, {'Biomarker': 'CYP4F3', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': '... itself appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the ...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '10020751', '[PT] MedDRA': 'Hypersensitivity', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': '... in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '10020751', '[PT] MedDRA': 'Hypersensitivity', 'Section': 'Warning And Precaution', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': '... in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '10040108', '[PT] MedDRA': 'Serotonin syndrome', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': 'The majority of reports of serotonin syndrome related to 5-HT3 receptor antagonist use occurred in a post-anesthesia ...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '10040108', '[PT] MedDRA': 'Serotonin syndrome', 'Section': 'Warning And Precaution', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': 'The majority of reports of serotonin syndrome related to 5-HT3 receptor antagonist use occurred in a post-anesthesia ...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': 'Ondansetron is a selective 5-HT3 receptor antagonist.'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Drug Interaction', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': '... following the concomitant use of 5-HT3 receptor antagonists and other serotonergic drugs, ...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': 'Ondansetron tablets are 5-HT3 receptor antagonist indicated for the prevention of...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': '... syndrome has been reported with 5-HT3 receptor antagonists alone.'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': '... of serotonin syndrome related to 5-HT3 receptor antagonist use occurred in a post-anesthesia ...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': '... following the concomitant use of 5-HT3 receptor antagonists and other serotonergic drugs, ...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': 'Ondansetron is a selective 5-HT3 receptor antagonist.'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Warning And Precaution', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': 'Serotonin syndrome : Reported with 5-HT3 receptor antagonists alone but particularly with concomitant ...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Warning And Precaution', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': '... syndrome has been reported with 5-HT3 receptor antagonists alone.'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Warning And Precaution', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': '... of serotonin syndrome related to 5-HT3 receptor antagonist use occurred in a post-anesthesia ...'}, {'Biomarker': 'HTR3A', 'Relation': 'blocker', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Description', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': '... of ondansetron and a selective blocking agent of the serotonin 5-HT3 receptor type.'}, {'Biomarker': 'LOC107987479', 'Relation': 'deficient', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': '... one enzyme (e.g., CYP2D6 genetic deficiency) will be compensated by ...'}, {'Biomarker': 'LOC107987479', 'Relation': 'deficient', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': '... one enzyme (e.g., CYP2D6 genetic deficiency) will be compensated by ...'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10028997', '[PT] MedDRA': 'Neoplasm malignant', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': 'highly emetogenic cancer chemotherapy, including cisplatin greater ...'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10028997', '[PT] MedDRA': 'Neoplasm malignant', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': '... repeat courses of moderately emetogenic cancer chemotherapy.'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10028997', '[PT] MedDRA': 'Neoplasm malignant', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': '... vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater ...'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10028997', '[PT] MedDRA': 'Neoplasm malignant', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': '... repeat courses of moderately emetogenic cancer chemotherapy.'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10047700', '[PT] MedDRA': 'Vomiting', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': '... indicated for the prevention of nausea and vomiting associated with:'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10047700', '[PT] MedDRA': 'Vomiting', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': 'nausea and vomiting associated with highly emetogenic cancer ...'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10047700', '[PT] MedDRA': 'Vomiting', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': 'nausea and vomiting associated with initial and repeat ...'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10047700', '[PT] MedDRA': 'Vomiting', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': 'nausea and vomiting associated with radiotherapy in patients ...'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10066962', '[PT] MedDRA': 'Procedural nausea', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': '... indicated for the prevention of postoperative nausea and/or vomiting.'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10066962', '[PT] MedDRA': 'Procedural nausea', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': 'postoperative nausea and/or vomiting.'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10066963', '[PT] MedDRA': 'Procedural vomiting', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': '... postoperative nausea and/or vomiting.'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10066963', '[PT] MedDRA': 'Procedural vomiting', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20200406', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=00327696-c496-4c83-a63e-9e29fd6246d4', 'Hit': 'postoperative nausea and/or vomiting.'}, {'Biomarker': 'CYP2D6', 'Relation': 'deficient', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': '... one enzyme (e.g., CYP2D6 genetic deficiency) will be compensated by ...'}, {'Biomarker': 'CYP2D6', 'Relation': 'deficient', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': '... one enzyme (e.g., CYP2D6 genetic deficiency) will be compensated by ...'}, {'Biomarker': 'CYP2D7', 'Relation': 'deficient', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': '... one enzyme (e.g., CYP2D6 genetic deficiency) will be compensated by ...'}, {'Biomarker': 'CYP2D7', 'Relation': 'deficient', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': '... one enzyme (e.g., CYP2D6 genetic deficiency) will be compensated by ...'}, {'Biomarker': 'CYP3A4', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': 'CYP 3A4 Inducers: Ondansetron elimination may be ...'}, {'Biomarker': 'CYP3A4', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': '... epileptic patients maintained chronically on CYP3A4 inducers, carbamazepine, or phenytoin...'}, {'Biomarker': 'CYP3A4', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Drug Interaction', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': 'In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, ...'}, {'Biomarker': 'CYP3A4', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': 'In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, ...'}, {'Biomarker': 'CYP3A4', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': 'CYP 3A4 Inducers: Ondansetron elimination may be ...'}, {'Biomarker': 'CYP3A4', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': '... epileptic patients maintained chronically on CYP3A4 inducers, carbamazepine, or phenytoin...'}, {'Biomarker': 'CYP4F3', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': '... elimination may be affected by cytochrome P-450 inducers.'}, {'Biomarker': 'CYP4F3', 'Relation': 'inducer', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': '... elimination may be affected by cytochrome P-450 inducers.'}, {'Biomarker': 'CYP4F3', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Drug Interaction', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': '... itself appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the ...'}, {'Biomarker': 'CYP4F3', 'Relation': 'inhibitor', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': '... itself appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the ...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '10020751', '[PT] MedDRA': 'Hypersensitivity', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': '... in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '10020751', '[PT] MedDRA': 'Hypersensitivity', 'Section': 'Warning And Precaution', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': '... in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '10040108', '[PT] MedDRA': 'Serotonin syndrome', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': 'The majority of reports of serotonin syndrome related to 5-HT3 receptor antagonist use occurred in a post-anesthesia ...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '10040108', '[PT] MedDRA': 'Serotonin syndrome', 'Section': 'Warning And Precaution', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': 'The majority of reports of serotonin syndrome related to 5-HT3 receptor antagonist use occurred in a post-anesthesia ...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': 'Ondansetron is a selective 5-HT3 receptor antagonist.'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Drug Interaction', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': '... following the concomitant use of 5-HT3 receptor antagonists and other serotonergic drugs, ...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': 'Ondansetron tablets are 5-HT3 receptor antagonist indicated for the prevention of...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': '... syndrome has been reported with 5-HT3 receptor antagonists alone.'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': '... of serotonin syndrome related to 5-HT3 receptor antagonist use occurred in a post-anesthesia ...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': '... following the concomitant use of 5-HT3 receptor antagonists and other serotonergic drugs, ...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': 'Ondansetron is a selective 5-HT3 receptor antagonist.'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Warning And Precaution', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': 'Serotonin Syndrome : Reported with 5-HT3 receptor antagonists alone but particularly with concomitant ...'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Warning And Precaution', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': '... syndrome has been reported with 5-HT3 receptor antagonists alone.'}, {'Biomarker': 'HTR3A', 'Relation': 'antagonist', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Warning And Precaution', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': '... of serotonin syndrome related to 5-HT3 receptor antagonist use occurred in a post-anesthesia ...'}, {'Biomarker': 'HTR3A', 'Relation': 'blocker', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Description', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': '... of ondansetron and a selective blocking agent of the serotonin 5-HT3 receptor type.'}, {'Biomarker': 'LOC107987479', 'Relation': 'deficient', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Clinical Pharmacology', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': '... one enzyme (e.g., CYP2D6 genetic deficiency) will be compensated by ...'}, {'Biomarker': 'LOC107987479', 'Relation': 'deficient', '[NID] MedDRA': '', '[PT] MedDRA': '', 'Section': 'Other Section', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': '... one enzyme (e.g., CYP2D6 genetic deficiency) will be compensated by ...'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10028997', '[PT] MedDRA': 'Neoplasm malignant', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': 'highly emetogenic cancer chemotherapy, including cisplatin greater ...'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10028997', '[PT] MedDRA': 'Neoplasm malignant', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': '... repeat courses of moderately emetogenic cancer chemotherapy.'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10028997', '[PT] MedDRA': 'Neoplasm malignant', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': '... vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater ...'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10028997', '[PT] MedDRA': 'Neoplasm malignant', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': '... repeat courses of moderately emetogenic cancer chemotherapy (1)'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10047700', '[PT] MedDRA': 'Vomiting', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': '... indicated for the prevention of nausea and vomiting associated with:'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10047700', '[PT] MedDRA': 'Vomiting', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': 'nausea and vomiting associated with highly emetogenic cancer ...'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10047700', '[PT] MedDRA': 'Vomiting', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': 'nausea and vomiting associated with initial and repeat ...'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10047700', '[PT] MedDRA': 'Vomiting', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': 'nausea and vomiting associated with radiotherapy in patients ...'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10066962', '[PT] MedDRA': 'Procedural nausea', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': '... indicated for the prevention of postoperative nausea and/or vomiting.'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10066962', '[PT] MedDRA': 'Procedural nausea', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': 'postoperative nausea and/or vomiting (...'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10066963', '[PT] MedDRA': 'Procedural vomiting', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': '... postoperative nausea and/or vomiting.'}, {'Biomarker': '', 'Relation': '', '[NID] MedDRA': '10066963', '[PT] MedDRA': 'Procedural vomiting', 'Section': 'Indications & Usage', 'FDAID': 'ANDA076183', 'Label Revision Date': '20211124', 'Source': 'https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=162f2088-9fb1-47e7-b88c-45104be7e7bb', 'Hit': 'postoperative nausea and/or vomiting (1)'}]]\n"
     ]
    }
   ],
   "source": [
    "import requests\n",
    "\n",
    "# Define input FDAIDs\n",
    "input_fdaids = ['NDA204114', 'ANDA076183']\n",
    "\n",
    "# Define placeholder for output\n",
    "results_json = []\n",
    "\n",
    "# Make a request\n",
    "print(\"Posting request to extract biomarkers and related diseases from specified CT.gov documents...\")\n",
    "\n",
    "for fdaid in input_fdaids:\n",
    "    print(f\"Processing {fdaid}...\")\n",
    "    response = requests.get(api_marketplace_url, headers=mkp_headers, params={'FDAID': fdaid})\n",
    "    # Check the response\n",
    "    if response.status_code == 200:\n",
    "        print(\"Success!\")\n",
    "        body_json = response.json()\n",
    "        results_json.append(body_json)\n",
    "    else:\n",
    "        raise Exception(f\"Error: {response}\")\n",
    "\n",
    "print(results_json)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "cbba2236",
   "metadata": {},
   "source": [
    "Now that we have got the JSON responses from the FDA Drug Label Biomarker API, we could convert the useful information associated with the keys into a pandas dataframe."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "1810155f",
   "metadata": {
    "pycharm": {
     "name": "#%%\n"
    }
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Biomarker</th>\n",
       "      <th>Relation</th>\n",
       "      <th>[NID] MedDRA</th>\n",
       "      <th>[PT] MedDRA</th>\n",
       "      <th>Section</th>\n",
       "      <th>FDAID</th>\n",
       "      <th>Label Revision Date</th>\n",
       "      <th>Source</th>\n",
       "      <th>Hit</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>ABCB1</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... , trametinib is not an inhibitor of P-gp, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>ABCB1</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... , trametinib is not an inhibitor of P-gp, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>ABCG2</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... , trametinib is not an inhibitor of P-gp, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>ABCG2</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... , trametinib is not an inhibitor of P-gp, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>ALK</td>\n",
       "      <td>no mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... or MEK inhibitor, and absence of EGFR muta...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>ALK</td>\n",
       "      <td>no mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... or MEK inhibitor, and absence of EGFR muta...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>ALK</td>\n",
       "      <td>rearrangement</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... absence of EGFR mutation or ALK rearrangem...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>ALK</td>\n",
       "      <td>rearrangement</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... absence of EGFR mutation or ALK rearrangem...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>activation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... V600E mutations result in constitutive act...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>activation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... V600E mutations result in constitutive act...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>diagnostic</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... retrospectively using an FDA-approved comp...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>diagnostic</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... retrospectively using an FDA-approved comp...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... mechanism of intrinsic resistance to BRAF ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... ; prior treatment with a BRAF inhibitor or...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... ; prior treatment with a BRAF inhibitor or...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... , no prior exposure to BRAF or MEK inhibit...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... who received prior treatment with BRAF or ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... received prior treatment with a BRAF inhib...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... mechanism of intrinsic resistance to BRAF ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... ; prior treatment with a BRAF inhibitor or...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... ; prior treatment with a BRAF inhibitor or...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... , no prior exposure to BRAF or MEK inhibit...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... who received prior treatment with BRAF or ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... received prior treatment with a BRAF inhib...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>SPL Patient Package Insert</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... who already have received a BRAF inhibitor...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>level</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... than the ULN vs. ≤ ULN) and BRAF mutation ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>level</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... than the ULN vs. ≤ ULN) and BRAF mutation ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10002240</td>\n",
       "      <td>Anaplastic thyroid cancer</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... with locally advanced or metastatic anapla...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10025650</td>\n",
       "      <td>Malignant melanoma</td>\n",
       "      <td>Adverse Reaction</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Adjuvant Treatment of BRAF V600E or V600K Muta...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10025650</td>\n",
       "      <td>Malignant melanoma</td>\n",
       "      <td>Adverse Reaction</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... 435 patients with Stage III melanoma with ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10025650</td>\n",
       "      <td>Malignant melanoma</td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... metastatic (Stage IV) BRAF V600E or V600K ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10025650</td>\n",
       "      <td>Malignant melanoma</td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... dabrafenib for the treatment of BRAF V600E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10025650</td>\n",
       "      <td>Malignant melanoma</td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Adjuvant Treatment of BRAF V600E or V600K Muta...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10025650</td>\n",
       "      <td>Malignant melanoma</td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... enrolled patients with Stage III melanoma ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10025650</td>\n",
       "      <td>Malignant melanoma</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Adjuvant Treatment of BRAF V600E or V600K Muta...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10025650</td>\n",
       "      <td>Malignant melanoma</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... adjuvant treatment of patients with melano...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10025650</td>\n",
       "      <td>Malignant melanoma</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... tests for the detection of BRAF V600 mutat...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10025650</td>\n",
       "      <td>Malignant melanoma</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Adjuvant Treatment of BRAF V600E or V600K Muta...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10025650</td>\n",
       "      <td>Malignant melanoma</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... 435 patients with Stage III melanoma with ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10025650</td>\n",
       "      <td>Malignant melanoma</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... metastatic (Stage IV) BRAF V600E or V600K ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10025650</td>\n",
       "      <td>Malignant melanoma</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... dabrafenib for the treatment of BRAF V600E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10025650</td>\n",
       "      <td>Malignant melanoma</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Adjuvant Treatment of BRAF V600E or V600K Muta...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10025650</td>\n",
       "      <td>Malignant melanoma</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... enrolled patients with Stage III melanoma ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>43</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10028980</td>\n",
       "      <td>Neoplasm</td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>BRAF V600E Mutation-Positive Unresectable or M...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10028980</td>\n",
       "      <td>Neoplasm</td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... dabrafenib for the treatment of BRAF V600E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>45</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10028980</td>\n",
       "      <td>Neoplasm</td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... in adult patients with selected tumors wit...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>46</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10028980</td>\n",
       "      <td>Neoplasm</td>\n",
       "      <td>Dosage &amp; Administration</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Confirm the presence of BRAF V600E or V600K mu...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>47</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10028980</td>\n",
       "      <td>Neoplasm</td>\n",
       "      <td>Dosage &amp; Administration</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Confirm the presence of BRAF V600E mutation in...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>48</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10028980</td>\n",
       "      <td>Neoplasm</td>\n",
       "      <td>Dosage &amp; Administration</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Confirm the presence of BRAF V600E mutation in...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>49</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10028980</td>\n",
       "      <td>Neoplasm</td>\n",
       "      <td>Dosage &amp; Administration</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Confirm the presence of BRAF V600E mutation in...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10028980</td>\n",
       "      <td>Neoplasm</td>\n",
       "      <td>Dosage &amp; Administration</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... test for the detection of BRAF V600E mutat...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>51</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10028980</td>\n",
       "      <td>Neoplasm</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... older with unresectable or metastatic soli...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>52</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10028980</td>\n",
       "      <td>Neoplasm</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>BRAF V600E Mutation-Positive Unresectable or M...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>53</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10028980</td>\n",
       "      <td>Neoplasm</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... older with unresectable or metastatic soli...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>54</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10028980</td>\n",
       "      <td>Neoplasm</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Confirm the presence of BRAF V600E or V600K mu...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>55</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10028980</td>\n",
       "      <td>Neoplasm</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Confirm the presence of BRAF V600E mutation in...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>56</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10028980</td>\n",
       "      <td>Neoplasm</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Confirm the presence of BRAF V600E mutation in...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>57</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10028980</td>\n",
       "      <td>Neoplasm</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Confirm the presence of BRAF V600E mutation in...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>58</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10028980</td>\n",
       "      <td>Neoplasm</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... test for the detection of BRAF V600E mutat...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>59</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10028980</td>\n",
       "      <td>Neoplasm</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>BRAF V600E Mutation-Positive Unresectable or M...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>60</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10028980</td>\n",
       "      <td>Neoplasm</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>BRAF V600E Mutation-Positive Unresectable or M...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>61</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10028980</td>\n",
       "      <td>Neoplasm</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... dabrafenib for the treatment of BRAF V600E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>62</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10028980</td>\n",
       "      <td>Neoplasm</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... in adult patients with selected tumors wit...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>63</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10028980</td>\n",
       "      <td>Neoplasm</td>\n",
       "      <td>Recent Major Change</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Indications and Usage, BRAF V600E Mutation-Pos...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>64</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10028980</td>\n",
       "      <td>Neoplasm</td>\n",
       "      <td>Use In Specific Population</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>BRAF V600E Mutation-Positive Unresectable or M...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>65</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10028997</td>\n",
       "      <td>Neoplasm malignant</td>\n",
       "      <td>Adverse Reaction</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... study in adult patients with cancers with ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>66</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10028997</td>\n",
       "      <td>Neoplasm malignant</td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... ) in patients with rare cancers with the B...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>67</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10028997</td>\n",
       "      <td>Neoplasm malignant</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... study in adult patients with cancers with ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>68</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10028997</td>\n",
       "      <td>Neoplasm malignant</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... ) in patients with rare cancers with the B...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>69</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10061289</td>\n",
       "      <td>Metastatic neoplasm</td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... dabrafenib for the treatment of BRAF V600E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>70</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10061289</td>\n",
       "      <td>Metastatic neoplasm</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>the treatment of patients with metastatic non-...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>71</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10061289</td>\n",
       "      <td>Metastatic neoplasm</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... patients with locally advanced or metastat...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>72</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10061289</td>\n",
       "      <td>Metastatic neoplasm</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... and older with unresectable or metastatic ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>73</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10061289</td>\n",
       "      <td>Metastatic neoplasm</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>BRAF V600E Mutation-Positive Metastatic NSCLC</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>74</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10061289</td>\n",
       "      <td>Metastatic neoplasm</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... dabrafenib for the treatment of BRAF V600E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10061289</td>\n",
       "      <td>Metastatic neoplasm</td>\n",
       "      <td>Recent Major Change</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Indications and Usage, BRAF V600E Mutation-Pos...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>76</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10061873</td>\n",
       "      <td>Non-small cell lung cancer</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... treatment of patients with metastatic non-...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>77</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Adverse Reaction</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... open-label trial of patients with BRAF V60...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>78</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>BRAF V600E or V600K Mutation-Positive Unresect...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>79</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... ) in 322 patients with BRAF V600E or V600K...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>80</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Tumor tissue was evaluated for BRAF mutations ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>81</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>The distribution of BRAF V600 mutations was BR...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>82</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>The distribution of BRAF V600 mutations was BR...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>83</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... vs. ≤ ULN) and BRAF mutation subtype (V600...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>84</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Randomization was stratified by BRAF mutation ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>85</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... unknown (1%); BRAF V600E mutation (91%), B...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>86</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... mutation (91%), BRAF V600K mutation (9%); ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>87</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... IIIB vs. IIIC – and BRAF V600 mutation typ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>88</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... patients with retrospectively centrally co...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>89</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>BRAF V600E Mutation-Positive Locally Advanced ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>90</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... trial in 40 patients with BRAF V600E or V6...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>91</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... , and the distribution of BRAF V600 mutati...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>92</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... based on local assessments of BRAF V600E m...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>93</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... a central laboratory confirmed the BRAF V6...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>94</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... that enrolled patients with a BRAF V600E m...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>95</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>BRAF mutation status for enrollment was determ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>96</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... dabrafenib in patients with a BRAF V600E m...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>97</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... patients with LGG with a BRAF V600E mutation.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>98</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>For patients with BRAF V600E mutant LGG and HG...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>99</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>BRAF V600E or V600K Mutation-Positive Unresect...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>100</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... cancer (NSCLC) with BRAF V600E mutation as...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>101</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>BRAF V600E Mutation-Positive Locally Advanced ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>102</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... cancer (ATC) with BRAF V600E mutation and ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>103</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... tests for the detection of BRAF V600E muta...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>104</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... test for the detection of BRAF V600E mutat...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>105</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... open-label trial of patients with BRAF V60...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>106</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>BRAF V600E mutations result in constitutive ac...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>107</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>BRAF V600E or V600K Mutation-Positive Unresect...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>108</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... ) in 322 patients with BRAF V600E or V600K...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>109</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Tumor tissue was evaluated for BRAF mutations ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>110</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>The distribution of BRAF V600 mutations was BR...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>111</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>The distribution of BRAF V600 mutations was BR...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>112</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... vs. ≤ ULN) and BRAF mutation subtype (V600...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>113</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Randomization was stratified by BRAF mutation ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>114</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... unknown (1%); BRAF V600E mutation (91%), B...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>115</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... mutation (91%), BRAF V600K mutation (9%); ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>116</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... IIIB vs. IIIC – and BRAF V600 mutation typ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>117</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... patients with retrospectively centrally co...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>118</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>BRAF V600E Mutation-Positive Locally Advanced ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>119</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... trial in 40 patients with BRAF V600E or V6...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>120</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... , and the distribution of BRAF V600 mutati...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>121</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... based on local assessments of BRAF V600E m...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>122</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... a central laboratory confirmed the BRAF V6...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>123</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... that enrolled patients with a BRAF V600E m...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>124</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>BRAF mutation status for enrollment was determ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>125</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... dabrafenib in patients with a BRAF V600E m...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>126</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... patients with LGG with a BRAF V600E mutation.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>127</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>For patients with BRAF V600E mutant LGG and HG...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>128</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10025650</td>\n",
       "      <td>Malignant melanoma</td>\n",
       "      <td>Dosage &amp; Administration</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... tests for the detection of BRAF V600 mutat...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>129</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10025650</td>\n",
       "      <td>Malignant melanoma</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... adjuvant treatment of patients with melano...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>130</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10025650</td>\n",
       "      <td>Malignant melanoma</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Adjuvant Treatment of BRAF V600E or V600K Muta...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>131</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10027480</td>\n",
       "      <td>Metastatic malignant melanoma</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... treatment-naïve patients with unresectable...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>132</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10027480</td>\n",
       "      <td>Metastatic malignant melanoma</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... of patients with unresectable or metastati...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>133</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10027480</td>\n",
       "      <td>Metastatic malignant melanoma</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>BRAF V600E or V600K Mutation-Positive Unresect...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>134</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td>10027480</td>\n",
       "      <td>Metastatic malignant melanoma</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... of patients with unresectable or metastati...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>135</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>BRAF V600E mutations result in constitutive ac...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>136</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Dosage &amp; Administration</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... tests for the detection of BRAF V600E muta...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>137</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Dosage &amp; Administration</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... test for the detection of BRAF V600E mutat...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>138</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>positive</td>\n",
       "      <td>10025650</td>\n",
       "      <td>Malignant melanoma</td>\n",
       "      <td>Adverse Reaction</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Adjuvant Treatment of BRAF V600E or V600K Muta...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>139</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>positive</td>\n",
       "      <td>10025650</td>\n",
       "      <td>Malignant melanoma</td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... metastatic (Stage IV) BRAF V600E or V600K ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>140</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>positive</td>\n",
       "      <td>10025650</td>\n",
       "      <td>Malignant melanoma</td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... dabrafenib for the treatment of BRAF V600E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>141</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>positive</td>\n",
       "      <td>10025650</td>\n",
       "      <td>Malignant melanoma</td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Adjuvant Treatment of BRAF V600E or V600K Muta...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>142</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>positive</td>\n",
       "      <td>10025650</td>\n",
       "      <td>Malignant melanoma</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Adjuvant Treatment of BRAF V600E or V600K Muta...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>143</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>positive</td>\n",
       "      <td>10025650</td>\n",
       "      <td>Malignant melanoma</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Adjuvant Treatment of BRAF V600E or V600K Muta...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>144</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>positive</td>\n",
       "      <td>10025650</td>\n",
       "      <td>Malignant melanoma</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Adjuvant Treatment of BRAF V600E or V600K Muta...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>145</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>positive</td>\n",
       "      <td>10025650</td>\n",
       "      <td>Malignant melanoma</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... metastatic (Stage IV) BRAF V600E or V600K ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>146</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>positive</td>\n",
       "      <td>10025650</td>\n",
       "      <td>Malignant melanoma</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... dabrafenib for the treatment of BRAF V600E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>147</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>positive</td>\n",
       "      <td>10025650</td>\n",
       "      <td>Malignant melanoma</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Adjuvant Treatment of BRAF V600E or V600K Muta...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>148</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>positive</td>\n",
       "      <td>10027480</td>\n",
       "      <td>Metastatic malignant melanoma</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>BRAF V600E or V600K Mutation-Positive Unresect...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>149</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>positive</td>\n",
       "      <td>10028980</td>\n",
       "      <td>Neoplasm</td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>BRAF V600E Mutation-Positive Unresectable or M...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>150</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>positive</td>\n",
       "      <td>10028980</td>\n",
       "      <td>Neoplasm</td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... dabrafenib for the treatment of BRAF V600E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>151</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>positive</td>\n",
       "      <td>10028980</td>\n",
       "      <td>Neoplasm</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>BRAF V600E Mutation-Positive Unresectable or M...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>152</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>positive</td>\n",
       "      <td>10028980</td>\n",
       "      <td>Neoplasm</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>BRAF V600E Mutation-Positive Unresectable or M...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>153</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>positive</td>\n",
       "      <td>10028980</td>\n",
       "      <td>Neoplasm</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>BRAF V600E Mutation-Positive Unresectable or M...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>154</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>positive</td>\n",
       "      <td>10028980</td>\n",
       "      <td>Neoplasm</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... dabrafenib for the treatment of BRAF V600E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>155</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>positive</td>\n",
       "      <td>10028980</td>\n",
       "      <td>Neoplasm</td>\n",
       "      <td>Recent Major Change</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Indications and Usage, BRAF V600E Mutation-Pos...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>156</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>positive</td>\n",
       "      <td>10028980</td>\n",
       "      <td>Neoplasm</td>\n",
       "      <td>Use In Specific Population</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>BRAF V600E Mutation-Positive Unresectable or M...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>157</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>positive</td>\n",
       "      <td>10061289</td>\n",
       "      <td>Metastatic neoplasm</td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... dabrafenib for the treatment of BRAF V600E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>158</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>positive</td>\n",
       "      <td>10061289</td>\n",
       "      <td>Metastatic neoplasm</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>BRAF V600E Mutation-Positive Metastatic NSCLC</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>159</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>positive</td>\n",
       "      <td>10061289</td>\n",
       "      <td>Metastatic neoplasm</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... dabrafenib for the treatment of BRAF V600E...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>160</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>positive</td>\n",
       "      <td>10061289</td>\n",
       "      <td>Metastatic neoplasm</td>\n",
       "      <td>Recent Major Change</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Indications and Usage, BRAF V600E Mutation-Pos...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>161</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>positive</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Adverse Reaction</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... open-label trial of patients with BRAF V60...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>162</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>positive</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>BRAF V600E or V600K Mutation-Positive Unresect...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>163</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>positive</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... ) in 322 patients with BRAF V600E or V600K...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>164</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>positive</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... patients with retrospectively centrally co...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>165</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>positive</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>BRAF V600E Mutation-Positive Locally Advanced ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>166</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>positive</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... trial in 40 patients with BRAF V600E or V6...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>167</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>positive</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>BRAF V600E or V600K Mutation-Positive Unresect...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>168</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>positive</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>BRAF V600E Mutation-Positive Locally Advanced ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>169</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>positive</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... open-label trial of patients with BRAF V60...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>170</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>positive</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>BRAF V600E or V600K Mutation-Positive Unresect...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>171</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>positive</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... ) in 322 patients with BRAF V600E or V600K...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>172</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>positive</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... patients with retrospectively centrally co...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>173</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>positive</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>BRAF V600E Mutation-Positive Locally Advanced ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>174</th>\n",
       "      <td>BRAF</td>\n",
       "      <td>positive</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... trial in 40 patients with BRAF V600E or V6...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>175</th>\n",
       "      <td>CYP1A2</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... , but is not an inhibitor of CYP1A2, CYP2A...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>176</th>\n",
       "      <td>CYP1A2</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... , but is not an inhibitor of CYP1A2, CYP2A...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>177</th>\n",
       "      <td>CYP2A6</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... , but is not an inhibitor of CYP1A2, CYP2A...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>178</th>\n",
       "      <td>CYP2A6</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... , but is not an inhibitor of CYP1A2, CYP2A...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>179</th>\n",
       "      <td>CYP2B6</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... , but is not an inhibitor of CYP1A2, CYP2A...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>180</th>\n",
       "      <td>CYP2B6</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... , but is not an inhibitor of CYP1A2, CYP2A...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>181</th>\n",
       "      <td>CYP2C8</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... studies, trametinib is an inhibitor of CYP...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>182</th>\n",
       "      <td>CYP2C8</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... studies, trametinib is an inhibitor of CYP...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>183</th>\n",
       "      <td>CYP2C9</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... , but is not an inhibitor of CYP1A2, CYP2A...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>184</th>\n",
       "      <td>CYP2C9</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... , but is not an inhibitor of CYP1A2, CYP2A...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>185</th>\n",
       "      <td>CYP2C19</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... , but is not an inhibitor of CYP1A2, CYP2A...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>186</th>\n",
       "      <td>CYP2C19</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... , but is not an inhibitor of CYP1A2, CYP2A...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>187</th>\n",
       "      <td>CYP3A4</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Trametinib is an inducer of CYP3A in vitro .</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>188</th>\n",
       "      <td>CYP3A4</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Trametinib is an inducer of CYP3A in vitro .</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>189</th>\n",
       "      <td>EPHB2</td>\n",
       "      <td>phosphorylation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... biomarkers, including inhibition of phosph...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>190</th>\n",
       "      <td>EPHB2</td>\n",
       "      <td>phosphorylation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... biomarkers, including inhibition of phosph...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>191</th>\n",
       "      <td>GOT1</td>\n",
       "      <td>increase</td>\n",
       "      <td>10020635</td>\n",
       "      <td>Hyperglycaemia</td>\n",
       "      <td>Adverse Reaction</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... lymphopenia, increased ALT, increased AST,...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>192</th>\n",
       "      <td>GOT1</td>\n",
       "      <td>increase</td>\n",
       "      <td>10020635</td>\n",
       "      <td>Hyperglycaemia</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... lymphopenia, increased ALT, increased AST,...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>193</th>\n",
       "      <td>GOT1</td>\n",
       "      <td>increase</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Adverse Reaction</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... ), increased ALT and increased AST (each n...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>194</th>\n",
       "      <td>GOT1</td>\n",
       "      <td>increase</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Adverse Reaction</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... , increased ALT, and increased AST (each n...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>195</th>\n",
       "      <td>GOT1</td>\n",
       "      <td>increase</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Adverse Reaction</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Increased AST</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>196</th>\n",
       "      <td>GOT1</td>\n",
       "      <td>increase</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Adverse Reaction</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Increased AST</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>197</th>\n",
       "      <td>GOT1</td>\n",
       "      <td>increase</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Adverse Reaction</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Increased AST</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>198</th>\n",
       "      <td>GOT1</td>\n",
       "      <td>increase</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Adverse Reaction</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Increased AST</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>199</th>\n",
       "      <td>GOT1</td>\n",
       "      <td>increase</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Adverse Reaction</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... increased (6%), AST increased (4.2%) and e...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>200</th>\n",
       "      <td>GOT1</td>\n",
       "      <td>increase</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Adverse Reaction</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Increased AST</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>201</th>\n",
       "      <td>GOT1</td>\n",
       "      <td>increase</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... ), increased ALT and increased AST (each n...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>202</th>\n",
       "      <td>GOT1</td>\n",
       "      <td>increase</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... , increased ALT, and increased AST (each n...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>203</th>\n",
       "      <td>GOT1</td>\n",
       "      <td>increase</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Increased AST</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>204</th>\n",
       "      <td>GOT1</td>\n",
       "      <td>increase</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Increased AST</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>205</th>\n",
       "      <td>GOT1</td>\n",
       "      <td>increase</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Increased AST</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>206</th>\n",
       "      <td>GOT1</td>\n",
       "      <td>increase</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Increased AST</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>207</th>\n",
       "      <td>GOT1</td>\n",
       "      <td>increase</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... increased (6%), AST increased (4.2%) and e...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>208</th>\n",
       "      <td>GOT1</td>\n",
       "      <td>increase</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Increased AST</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>209</th>\n",
       "      <td>GOT1</td>\n",
       "      <td>level</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... impairment defined by bilirubin and AST le...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>210</th>\n",
       "      <td>GOT1</td>\n",
       "      <td>level</td>\n",
       "      <td>10019670</td>\n",
       "      <td>Hepatic function abnormal</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... bilirubin &gt; 1x to 1.5x ULN and any AST) he...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>211</th>\n",
       "      <td>GOT1</td>\n",
       "      <td>level</td>\n",
       "      <td>10019670</td>\n",
       "      <td>Hepatic function abnormal</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... bilirubin &gt; 3x to 10x ULN and any AST) hep...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>212</th>\n",
       "      <td>GOT1</td>\n",
       "      <td>level</td>\n",
       "      <td>10019670</td>\n",
       "      <td>Hepatic function abnormal</td>\n",
       "      <td>Use In Specific Population</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... bilirubin &gt; 1x to 1.5x ULN and any AST) he...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>213</th>\n",
       "      <td>GOT1</td>\n",
       "      <td>level</td>\n",
       "      <td>10019670</td>\n",
       "      <td>Hepatic function abnormal</td>\n",
       "      <td>Use In Specific Population</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... bilirubin &gt; 3x to 10x ULN and any AST) hep...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>214</th>\n",
       "      <td>GOT1</td>\n",
       "      <td>level</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... ) and aspartate aminotransferase (AST) &gt; U...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>215</th>\n",
       "      <td>GOT1</td>\n",
       "      <td>level</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... bilirubin &gt; 1.5x to 3x ULN and any AST) or...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>216</th>\n",
       "      <td>GOT1</td>\n",
       "      <td>level</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... impairment defined by bilirubin and AST le...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>217</th>\n",
       "      <td>GOT1</td>\n",
       "      <td>level</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Use In Specific Population</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... ) and aspartate aminotransferase (AST) &gt; U...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>218</th>\n",
       "      <td>GOT1</td>\n",
       "      <td>level</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Use In Specific Population</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... bilirubin &gt; 1.5x to 3x ULN and any AST) or...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>219</th>\n",
       "      <td>GPT</td>\n",
       "      <td>increase</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Adverse Reaction</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Increased alanine aminotransferase (ALT)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>220</th>\n",
       "      <td>GPT</td>\n",
       "      <td>increase</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Adverse Reaction</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... n = 4), increased ALT and increased AST (e...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>221</th>\n",
       "      <td>GPT</td>\n",
       "      <td>increase</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Adverse Reaction</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... neutropenia, thrombocytopenia, increased A...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>222</th>\n",
       "      <td>GPT</td>\n",
       "      <td>increase</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Adverse Reaction</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Increased ALT</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>223</th>\n",
       "      <td>GPT</td>\n",
       "      <td>increase</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Adverse Reaction</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Increased ALT</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>224</th>\n",
       "      <td>GPT</td>\n",
       "      <td>increase</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Adverse Reaction</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Increased ALT</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>225</th>\n",
       "      <td>GPT</td>\n",
       "      <td>increase</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Adverse Reaction</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Increased ALT</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>226</th>\n",
       "      <td>GPT</td>\n",
       "      <td>increase</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Adverse Reaction</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... &gt; 3% of patients included ALT increased (6...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>227</th>\n",
       "      <td>GPT</td>\n",
       "      <td>increase</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Adverse Reaction</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Increased ALT</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>228</th>\n",
       "      <td>GPT</td>\n",
       "      <td>increase</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Increased alanine aminotransferase (ALT)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>229</th>\n",
       "      <td>GPT</td>\n",
       "      <td>increase</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... n = 4), increased ALT and increased AST (e...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>230</th>\n",
       "      <td>GPT</td>\n",
       "      <td>increase</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... neutropenia, thrombocytopenia, increased A...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>231</th>\n",
       "      <td>GPT</td>\n",
       "      <td>increase</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Increased ALT</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>232</th>\n",
       "      <td>GPT</td>\n",
       "      <td>increase</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Increased ALT</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>233</th>\n",
       "      <td>GPT</td>\n",
       "      <td>increase</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Increased ALT</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>234</th>\n",
       "      <td>GPT</td>\n",
       "      <td>increase</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Increased ALT</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>235</th>\n",
       "      <td>GPT</td>\n",
       "      <td>increase</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... &gt; 3% of patients included ALT increased (6...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>236</th>\n",
       "      <td>GPT</td>\n",
       "      <td>increase</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Increased ALT</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>237</th>\n",
       "      <td>KCNK3</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... , trametinib is not an inhibitor of P-gp, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>238</th>\n",
       "      <td>KCNK3</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... , trametinib is not an inhibitor of P-gp, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>239</th>\n",
       "      <td>MAP2K1</td>\n",
       "      <td>activation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... (MEK1) and MEK2 activation and of MEK1 and...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>240</th>\n",
       "      <td>MAP2K1</td>\n",
       "      <td>activation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... (MEK1) and MEK2 activation and of MEK1 and...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>241</th>\n",
       "      <td>MAP2K2</td>\n",
       "      <td>activation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... 1 (MEK1) and MEK2 activation and of MEK1 a...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>242</th>\n",
       "      <td>MAP2K2</td>\n",
       "      <td>activation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... 1 (MEK1) and MEK2 activation and of MEK1 a...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>243</th>\n",
       "      <td>MAP2K7</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... with a BRAF inhibitor or MEK inhibitor was...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>244</th>\n",
       "      <td>MAP2K7</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... prior exposure to BRAF or MEK inhibitor, a...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>245</th>\n",
       "      <td>MAP2K7</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... prior treatment with BRAF or MEK inhibitor...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>246</th>\n",
       "      <td>MAP2K7</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... with a BRAF inhibitor or MEK inhibitor was...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>247</th>\n",
       "      <td>MAP2K7</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... prior exposure to BRAF or MEK inhibitor, a...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>248</th>\n",
       "      <td>MAP2K7</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... prior treatment with BRAF or MEK inhibitor...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>249</th>\n",
       "      <td>MAP2K7</td>\n",
       "      <td>no mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Study</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... prior exposure to BRAF or MEK inhibitor, a...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>250</th>\n",
       "      <td>MAP2K7</td>\n",
       "      <td>no mutation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... prior exposure to BRAF or MEK inhibitor, a...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>251</th>\n",
       "      <td>MAPK1</td>\n",
       "      <td>phosphorylation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... biomarkers, including inhibition of phosph...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>252</th>\n",
       "      <td>MAPK1</td>\n",
       "      <td>phosphorylation</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... biomarkers, including inhibition of phosph...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>253</th>\n",
       "      <td>MAPK3</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Trametinib is a reversible inhibitor of mitoge...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>254</th>\n",
       "      <td>MAPK3</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Trametinib is a reversible inhibitor of mitoge...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>255</th>\n",
       "      <td>PAK2</td>\n",
       "      <td>increase</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... cell proliferation), and increases in p27 ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>256</th>\n",
       "      <td>PAK2</td>\n",
       "      <td>increase</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... cell proliferation), and increases in p27 ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>257</th>\n",
       "      <td>SLC22A6</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... , trametinib is not an inhibitor of P-gp, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>258</th>\n",
       "      <td>SLC22A6</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... , trametinib is not an inhibitor of P-gp, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>259</th>\n",
       "      <td>SLCO1B1</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... , trametinib is not an inhibitor of P-gp, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>260</th>\n",
       "      <td>SLCO1B1</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... , trametinib is not an inhibitor of P-gp, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>261</th>\n",
       "      <td>SLCO1B3</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... , trametinib is not an inhibitor of P-gp, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>262</th>\n",
       "      <td>SLCO1B3</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>NDA204114</td>\n",
       "      <td>20220622</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... , trametinib is not an inhibitor of P-gp, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>263</th>\n",
       "      <td>CYP3A4</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211006</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>CYP 3A4 Inducers: Ondansetron elimination may ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>264</th>\n",
       "      <td>CYP3A4</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211006</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... epileptic patients maintained chronically ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>265</th>\n",
       "      <td>CYP3A4</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Drug Interaction</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211006</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>In patients treated with potent inducers of CY...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>266</th>\n",
       "      <td>CYP4F3</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211006</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... elimination may be affected by cytochrome ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>267</th>\n",
       "      <td>CYP4F3</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Drug Interaction</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211006</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... itself appear to induce or inhibit the cyt...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>268</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td>10020751</td>\n",
       "      <td>Hypersensitivity</td>\n",
       "      <td>Warning And Precaution</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211006</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... in patients who have exhibited hypersensit...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>269</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td>10040108</td>\n",
       "      <td>Serotonin syndrome</td>\n",
       "      <td>Warning And Precaution</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211006</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>The majority of reports of serotonin syndrome ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>270</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Drug Interaction</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211006</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... following the concomitant use of 5-HT3 rec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>271</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>SPL Unclassified</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211006</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Ondansetron tablets are 5-HT3 receptor antagon...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>272</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>SPL Unclassified</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211006</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Serotonin syndrome: Reported with 5-HT3 recept...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>273</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Warning And Precaution</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211006</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... syndrome has been reported with 5-HT3 rece...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>274</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Warning And Precaution</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211006</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... of serotonin syndrome related to 5-HT3 rec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>275</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>blocker</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Description</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211006</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... of ondansetron and a selective blocking ag...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>276</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10028997</td>\n",
       "      <td>Neoplasm malignant</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211006</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>highly emetogenic cancer chemotherapy, includi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>277</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10028997</td>\n",
       "      <td>Neoplasm malignant</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211006</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... repeat courses of moderately emetogenic ca...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>278</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10047700</td>\n",
       "      <td>Vomiting</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211006</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... indicated for the prevention of nausea and...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>279</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10066962</td>\n",
       "      <td>Procedural nausea</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211006</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... indicated for the prevention of postoperat...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>280</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10066963</td>\n",
       "      <td>Procedural vomiting</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211006</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... postoperative nausea and/or vomiting.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>281</th>\n",
       "      <td>CYP2D6</td>\n",
       "      <td>deficient</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... one enzyme (e.g., CYP2D6 genetic deficienc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>282</th>\n",
       "      <td>CYP2D6</td>\n",
       "      <td>deficient</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... one enzyme (e.g., CYP2D6 genetic deficienc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>283</th>\n",
       "      <td>CYP2D7</td>\n",
       "      <td>deficient</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... one enzyme (e.g., CYP2D6 genetic deficienc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>284</th>\n",
       "      <td>CYP2D7</td>\n",
       "      <td>deficient</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... one enzyme (e.g., CYP2D6 genetic deficienc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>285</th>\n",
       "      <td>CYP3A4</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... epileptic patients maintained chronically ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>286</th>\n",
       "      <td>CYP3A4</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... epileptic patients maintained chronically ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>287</th>\n",
       "      <td>CYP3A4</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>In patients treated with potent inducers of CY...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>288</th>\n",
       "      <td>CYP3A4</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Precaution</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>In patients treated with potent inducers of CY...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>289</th>\n",
       "      <td>CYP4F3</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... elimination may be affected by cytochrome ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>290</th>\n",
       "      <td>CYP4F3</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... elimination may be affected by cytochrome ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>291</th>\n",
       "      <td>CYP4F3</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... itself appear to induce or inhibit the cyt...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>292</th>\n",
       "      <td>CYP4F3</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Precaution</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... itself appear to induce or inhibit the cyt...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>293</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td>10020751</td>\n",
       "      <td>Hypersensitivity</td>\n",
       "      <td>Warning</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... in patients who have exhibited hypersensit...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>294</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td>10040108</td>\n",
       "      <td>Serotonin syndrome</td>\n",
       "      <td>Warning</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>The majority of reports of serotonin syndrome ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>295</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Ondansetron is a selective 5-HT3 receptor anta...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>296</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... or pretreatment with a serotonin 5-HT3 rec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>297</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Ondansetron is a selective 5-HT3 receptor anta...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>298</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... or pretreatment with a serotonin 5-HT3 rec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>299</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... following the concomitant use of 5-HT3 rec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>300</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Precaution</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... following the concomitant use of 5-HT3 rec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>301</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Warning</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... syndrome has been reported with 5-HT3 rece...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>302</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Warning</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... of serotonin syndrome related to 5-HT3 rec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>303</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>blocker</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Description</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... of ondansetron and a selective blocking ag...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>304</th>\n",
       "      <td>LOC107987479</td>\n",
       "      <td>deficient</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... one enzyme (e.g., CYP2D6 genetic deficienc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>305</th>\n",
       "      <td>LOC107987479</td>\n",
       "      <td>deficient</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... one enzyme (e.g., CYP2D6 genetic deficienc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>306</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10028813</td>\n",
       "      <td>Nausea</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... there is little expectation that nausea an...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>307</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10028813</td>\n",
       "      <td>Nausea</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>In patients where nausea and/or vomiting must ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>308</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10028997</td>\n",
       "      <td>Neoplasm malignant</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... vomiting associated with highly emetogenic...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>309</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10028997</td>\n",
       "      <td>Neoplasm malignant</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... repeat courses of moderately emetogenic ca...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>310</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10047700</td>\n",
       "      <td>Vomiting</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Prevention of nausea and vomiting associated w...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>311</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10047700</td>\n",
       "      <td>Vomiting</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Prevention of nausea and vomiting associated w...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>312</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10047700</td>\n",
       "      <td>Vomiting</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Prevention of nausea and vomiting associated w...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>313</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10047700</td>\n",
       "      <td>Vomiting</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... that nausea and/or vomiting will occur pos...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>314</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10047700</td>\n",
       "      <td>Vomiting</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... where nausea and/or vomiting must be avoid...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>315</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10066962</td>\n",
       "      <td>Procedural nausea</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Prevention of postoperative nausea and/or vomi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>316</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10066962</td>\n",
       "      <td>Procedural nausea</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... even where the incidence of postoperative ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>317</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10066963</td>\n",
       "      <td>Procedural vomiting</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... postoperative nausea and/or vomiting.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>318</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10066963</td>\n",
       "      <td>Procedural vomiting</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20190429</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... postoperative nausea and/or vomiting is low.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>319</th>\n",
       "      <td>CYP2D6</td>\n",
       "      <td>deficient</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... one enzyme (e.g., CYP2D6 genetic deficienc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>320</th>\n",
       "      <td>CYP2D6</td>\n",
       "      <td>deficient</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... one enzyme (e.g., CYP2D6 genetic deficienc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>321</th>\n",
       "      <td>CYP2D7</td>\n",
       "      <td>deficient</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... one enzyme (e.g., CYP2D6 genetic deficienc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>322</th>\n",
       "      <td>CYP2D7</td>\n",
       "      <td>deficient</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... one enzyme (e.g., CYP2D6 genetic deficienc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>323</th>\n",
       "      <td>CYP3A4</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>CYP 3A4 Inducers: Ondansetron elimination may ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>324</th>\n",
       "      <td>CYP3A4</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... epileptic patients maintained chronically ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>325</th>\n",
       "      <td>CYP3A4</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Drug Interaction</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>In patients treated with potent inducers of CY...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>326</th>\n",
       "      <td>CYP3A4</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>In patients treated with potent inducers of CY...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>327</th>\n",
       "      <td>CYP3A4</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>CYP 3A4 Inducers: Ondansetron elimination may ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>328</th>\n",
       "      <td>CYP3A4</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... epileptic patients maintained chronically ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>329</th>\n",
       "      <td>CYP4F3</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... elimination may be affected by cytochrome ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>330</th>\n",
       "      <td>CYP4F3</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... elimination may be affected by cytochrome ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>331</th>\n",
       "      <td>CYP4F3</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Drug Interaction</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... itself appear to induce or inhibit the cyt...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>332</th>\n",
       "      <td>CYP4F3</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... itself appear to induce or inhibit the cyt...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>333</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td>10020751</td>\n",
       "      <td>Hypersensitivity</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... in patients who have exhibited hypersensit...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>334</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td>10020751</td>\n",
       "      <td>Hypersensitivity</td>\n",
       "      <td>Warning And Precaution</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... in patients who have exhibited hypersensit...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>335</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td>10040108</td>\n",
       "      <td>Serotonin syndrome</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>The majority of reports of serotonin syndrome ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>336</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td>10040108</td>\n",
       "      <td>Serotonin syndrome</td>\n",
       "      <td>Warning And Precaution</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>The majority of reports of serotonin syndrome ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>337</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Ondansetron is a selective 5-HT3 receptor anta...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>338</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Drug Interaction</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... following the concomitant use of 5-HT3 rec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>339</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Ondansetron tablets are 5-HT3 receptor antagon...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>340</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... syndrome has been reported with 5-HT3 rece...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>341</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... of serotonin syndrome related to 5-HT3 rec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>342</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... following the concomitant use of 5-HT3 rec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>343</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Ondansetron is a selective 5-HT3 receptor anta...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>344</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Warning And Precaution</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Serotonin Syndrome : Reported with 5-HT3 recep...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>345</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Warning And Precaution</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... syndrome has been reported with 5-HT3 rece...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>346</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Warning And Precaution</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... of serotonin syndrome related to 5-HT3 rec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>347</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>blocker</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Description</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... of ondansetron and a selective blocking ag...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>348</th>\n",
       "      <td>LOC107987479</td>\n",
       "      <td>deficient</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... one enzyme (e.g., CYP2D6 genetic deficienc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>349</th>\n",
       "      <td>LOC107987479</td>\n",
       "      <td>deficient</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... one enzyme (e.g., CYP2D6 genetic deficienc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>350</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10028997</td>\n",
       "      <td>Neoplasm malignant</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>highly emetogenic cancer chemotherapy, includi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>351</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10028997</td>\n",
       "      <td>Neoplasm malignant</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... repeat courses of moderately emetogenic ca...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>352</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10028997</td>\n",
       "      <td>Neoplasm malignant</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... vomiting associated with highly emetogenic...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>353</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10028997</td>\n",
       "      <td>Neoplasm malignant</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... repeat courses of moderately emetogenic ca...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>354</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10047700</td>\n",
       "      <td>Vomiting</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... indicated for the prevention of nausea and...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>355</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10047700</td>\n",
       "      <td>Vomiting</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>nausea and vomiting associated with highly eme...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>356</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10047700</td>\n",
       "      <td>Vomiting</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>nausea and vomiting associated with initial an...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>357</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10047700</td>\n",
       "      <td>Vomiting</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>nausea and vomiting associated with radiothera...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>358</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10066962</td>\n",
       "      <td>Procedural nausea</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... indicated for the prevention of postoperat...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>359</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10066962</td>\n",
       "      <td>Procedural nausea</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>postoperative nausea and/or vomiting (...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>360</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10066963</td>\n",
       "      <td>Procedural vomiting</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... postoperative nausea and/or vomiting.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>361</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10066963</td>\n",
       "      <td>Procedural vomiting</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20220503</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>postoperative nausea and/or vomiting (1)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>362</th>\n",
       "      <td>CYP2D6</td>\n",
       "      <td>deficient</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... one enzyme (e.g., CYP2D6 genetic deficienc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>363</th>\n",
       "      <td>CYP2D6</td>\n",
       "      <td>deficient</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... one enzyme (e.g., CYP2D6 genetic deficienc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>364</th>\n",
       "      <td>CYP2D7</td>\n",
       "      <td>deficient</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... one enzyme (e.g., CYP2D6 genetic deficienc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>365</th>\n",
       "      <td>CYP2D7</td>\n",
       "      <td>deficient</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... one enzyme (e.g., CYP2D6 genetic deficienc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>366</th>\n",
       "      <td>CYP3A4</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>CYP 3A4 Inducers: Ondansetron elimination may ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>367</th>\n",
       "      <td>CYP3A4</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... epileptic patients maintained chronically ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>368</th>\n",
       "      <td>CYP3A4</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Drug Interaction</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>In patients treated with potent inducers of CY...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>369</th>\n",
       "      <td>CYP3A4</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>In patients treated with potent inducers of CY...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>370</th>\n",
       "      <td>CYP3A4</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>CYP 3A4 Inducers: Ondansetron elimination may ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>371</th>\n",
       "      <td>CYP3A4</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... epileptic patients maintained chronically ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>372</th>\n",
       "      <td>CYP4F3</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... elimination may be affected by cytochrome ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>373</th>\n",
       "      <td>CYP4F3</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... elimination may be affected by cytochrome ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>374</th>\n",
       "      <td>CYP4F3</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Drug Interaction</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... itself appear to induce or inhibit the cyt...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>375</th>\n",
       "      <td>CYP4F3</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... itself appear to induce or inhibit the cyt...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>376</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td>10020751</td>\n",
       "      <td>Hypersensitivity</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... in patients who have exhibited hypersensit...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>377</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td>10020751</td>\n",
       "      <td>Hypersensitivity</td>\n",
       "      <td>Warning And Precaution</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... in patients who have exhibited hypersensit...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>378</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td>10040108</td>\n",
       "      <td>Serotonin syndrome</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>The majority of reports of serotonin syndrome ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>379</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td>10040108</td>\n",
       "      <td>Serotonin syndrome</td>\n",
       "      <td>Warning And Precaution</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>The majority of reports of serotonin syndrome ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>380</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Ondansetron is a selective 5-HT3 receptor anta...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>381</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Drug Interaction</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... following the concomitant use of 5-HT3 rec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>382</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Ondansetron tablets are 5-HT3 receptor antagon...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>383</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... syndrome has been reported with 5-HT3 rece...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>384</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... of serotonin syndrome related to 5-HT3 rec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>385</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... following the concomitant use of 5-HT3 rec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>386</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Ondansetron is a selective 5-HT3 receptor anta...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>387</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Warning And Precaution</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Serotonin Syndrome : Reported with 5-HT3 recep...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>388</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Warning And Precaution</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... syndrome has been reported with 5-HT3 rece...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Warning And Precaution</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... of serotonin syndrome related to 5-HT3 rec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>390</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>blocker</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Description</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... of ondansetron and a selective blocking ag...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>391</th>\n",
       "      <td>LOC107987479</td>\n",
       "      <td>deficient</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... one enzyme (e.g., CYP2D6 genetic deficienc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>392</th>\n",
       "      <td>LOC107987479</td>\n",
       "      <td>deficient</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... one enzyme (e.g., CYP2D6 genetic deficienc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>393</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10028997</td>\n",
       "      <td>Neoplasm malignant</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>highly emetogenic cancer chemotherapy, includi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>394</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10028997</td>\n",
       "      <td>Neoplasm malignant</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... repeat courses of moderately emetogenic ca...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>395</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10028997</td>\n",
       "      <td>Neoplasm malignant</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... vomiting associated with highly emetogenic...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>396</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10028997</td>\n",
       "      <td>Neoplasm malignant</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... repeat courses of moderately emetogenic ca...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>397</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10047700</td>\n",
       "      <td>Vomiting</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... indicated for the prevention of nausea and...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>398</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10047700</td>\n",
       "      <td>Vomiting</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>nausea and vomiting associated with highly eme...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>399</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10047700</td>\n",
       "      <td>Vomiting</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>nausea and vomiting associated with initial an...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>400</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10047700</td>\n",
       "      <td>Vomiting</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>nausea and vomiting associated with radiothera...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>401</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10066962</td>\n",
       "      <td>Procedural nausea</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... indicated for the prevention of postoperat...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>402</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10066962</td>\n",
       "      <td>Procedural nausea</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>postoperative nausea and/or vomiting (...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>403</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10066963</td>\n",
       "      <td>Procedural vomiting</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... postoperative nausea and/or vomiting.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>404</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10066963</td>\n",
       "      <td>Procedural vomiting</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20210525</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>postoperative nausea and/or vomiting (1)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>405</th>\n",
       "      <td>CYP2D6</td>\n",
       "      <td>deficient</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... one enzyme (e.g., CYP2D6 genetic deficienc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>406</th>\n",
       "      <td>CYP2D6</td>\n",
       "      <td>deficient</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... one enzyme (e.g., CYP2D6 genetic deficienc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>407</th>\n",
       "      <td>CYP2D7</td>\n",
       "      <td>deficient</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... one enzyme (e.g., CYP2D6 genetic deficienc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>408</th>\n",
       "      <td>CYP2D7</td>\n",
       "      <td>deficient</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... one enzyme (e.g., CYP2D6 genetic deficienc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>409</th>\n",
       "      <td>CYP3A4</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>CYP 3A4 Inducers: Ondansetron elimination may ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>410</th>\n",
       "      <td>CYP3A4</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... epileptic patients maintained chronically ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>411</th>\n",
       "      <td>CYP3A4</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Drug Interaction</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>In patients treated with potent inducers of CY...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>412</th>\n",
       "      <td>CYP3A4</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>In patients treated with potent inducers of CY...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>413</th>\n",
       "      <td>CYP3A4</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>CYP 3A4 Inducers: Ondansetron elimination may ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>414</th>\n",
       "      <td>CYP3A4</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... epileptic patients maintained chronically ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>415</th>\n",
       "      <td>CYP4F3</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... elimination may be affected by cytochrome ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>416</th>\n",
       "      <td>CYP4F3</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... elimination may be affected by cytochrome ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>417</th>\n",
       "      <td>CYP4F3</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Drug Interaction</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... itself appear to induce or inhibit the cyt...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>418</th>\n",
       "      <td>CYP4F3</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... itself appear to induce or inhibit the cyt...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>419</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td>10020751</td>\n",
       "      <td>Hypersensitivity</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... in patients who have exhibited hypersensit...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>420</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td>10020751</td>\n",
       "      <td>Hypersensitivity</td>\n",
       "      <td>Warning And Precaution</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... in patients who have exhibited hypersensit...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>421</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td>10040108</td>\n",
       "      <td>Serotonin syndrome</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>The majority of reports of serotonin syndrome ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>422</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td>10040108</td>\n",
       "      <td>Serotonin syndrome</td>\n",
       "      <td>Warning And Precaution</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>The majority of reports of serotonin syndrome ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>423</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Ondansetron is a selective 5-HT3 receptor anta...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>424</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Drug Interaction</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... following the concomitant use of 5-HT3 rec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>425</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Ondansetron tablets are 5-HT3 receptor antagon...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>426</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... syndrome has been reported with 5-HT3 rece...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>427</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... of serotonin syndrome related to 5-HT3 rec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>428</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... following the concomitant use of 5-HT3 rec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>429</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Ondansetron is a selective 5-HT3 receptor anta...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>430</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Warning And Precaution</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Serotonin syndrome : Reported with 5-HT3 recep...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>431</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Warning And Precaution</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... syndrome has been reported with 5-HT3 rece...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>432</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Warning And Precaution</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... of serotonin syndrome related to 5-HT3 rec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>433</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>blocker</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Description</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... of ondansetron and a selective blocking ag...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>434</th>\n",
       "      <td>LOC107987479</td>\n",
       "      <td>deficient</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... one enzyme (e.g., CYP2D6 genetic deficienc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>435</th>\n",
       "      <td>LOC107987479</td>\n",
       "      <td>deficient</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... one enzyme (e.g., CYP2D6 genetic deficienc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>436</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10028997</td>\n",
       "      <td>Neoplasm malignant</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>highly emetogenic cancer chemotherapy, includi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>437</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10028997</td>\n",
       "      <td>Neoplasm malignant</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... repeat courses of moderately emetogenic ca...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>438</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10028997</td>\n",
       "      <td>Neoplasm malignant</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... vomiting associated with highly emetogenic...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>439</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10028997</td>\n",
       "      <td>Neoplasm malignant</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... repeat courses of moderately emetogenic ca...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>440</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10047700</td>\n",
       "      <td>Vomiting</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... indicated for the prevention of nausea and...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>441</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10047700</td>\n",
       "      <td>Vomiting</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>nausea and vomiting associated with highly eme...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>442</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10047700</td>\n",
       "      <td>Vomiting</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>nausea and vomiting associated with initial an...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>443</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10047700</td>\n",
       "      <td>Vomiting</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>nausea and vomiting associated with radiothera...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>444</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10066962</td>\n",
       "      <td>Procedural nausea</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... indicated for the prevention of postoperat...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>445</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10066962</td>\n",
       "      <td>Procedural nausea</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>postoperative nausea and/or vomiting.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>446</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10066963</td>\n",
       "      <td>Procedural vomiting</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... postoperative nausea and/or vomiting.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>447</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10066963</td>\n",
       "      <td>Procedural vomiting</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20200406</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>postoperative nausea and/or vomiting.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>448</th>\n",
       "      <td>CYP2D6</td>\n",
       "      <td>deficient</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... one enzyme (e.g., CYP2D6 genetic deficienc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>449</th>\n",
       "      <td>CYP2D6</td>\n",
       "      <td>deficient</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... one enzyme (e.g., CYP2D6 genetic deficienc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>450</th>\n",
       "      <td>CYP2D7</td>\n",
       "      <td>deficient</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... one enzyme (e.g., CYP2D6 genetic deficienc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>451</th>\n",
       "      <td>CYP2D7</td>\n",
       "      <td>deficient</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... one enzyme (e.g., CYP2D6 genetic deficienc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>452</th>\n",
       "      <td>CYP3A4</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>CYP 3A4 Inducers: Ondansetron elimination may ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>453</th>\n",
       "      <td>CYP3A4</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... epileptic patients maintained chronically ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>454</th>\n",
       "      <td>CYP3A4</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Drug Interaction</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>In patients treated with potent inducers of CY...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>455</th>\n",
       "      <td>CYP3A4</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>In patients treated with potent inducers of CY...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>456</th>\n",
       "      <td>CYP3A4</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>CYP 3A4 Inducers: Ondansetron elimination may ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>457</th>\n",
       "      <td>CYP3A4</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... epileptic patients maintained chronically ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>458</th>\n",
       "      <td>CYP4F3</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... elimination may be affected by cytochrome ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>459</th>\n",
       "      <td>CYP4F3</td>\n",
       "      <td>inducer</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... elimination may be affected by cytochrome ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>460</th>\n",
       "      <td>CYP4F3</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Drug Interaction</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... itself appear to induce or inhibit the cyt...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>461</th>\n",
       "      <td>CYP4F3</td>\n",
       "      <td>inhibitor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... itself appear to induce or inhibit the cyt...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>462</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td>10020751</td>\n",
       "      <td>Hypersensitivity</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... in patients who have exhibited hypersensit...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>463</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td>10020751</td>\n",
       "      <td>Hypersensitivity</td>\n",
       "      <td>Warning And Precaution</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... in patients who have exhibited hypersensit...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>464</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td>10040108</td>\n",
       "      <td>Serotonin syndrome</td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>The majority of reports of serotonin syndrome ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>465</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td>10040108</td>\n",
       "      <td>Serotonin syndrome</td>\n",
       "      <td>Warning And Precaution</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>The majority of reports of serotonin syndrome ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>466</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Ondansetron is a selective 5-HT3 receptor anta...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>467</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Drug Interaction</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... following the concomitant use of 5-HT3 rec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>468</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Ondansetron tablets are 5-HT3 receptor antagon...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>469</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... syndrome has been reported with 5-HT3 rece...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>470</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... of serotonin syndrome related to 5-HT3 rec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>471</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... following the concomitant use of 5-HT3 rec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>472</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Ondansetron is a selective 5-HT3 receptor anta...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>473</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Warning And Precaution</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>Serotonin Syndrome : Reported with 5-HT3 recep...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>474</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Warning And Precaution</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... syndrome has been reported with 5-HT3 rece...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>475</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>antagonist</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Warning And Precaution</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... of serotonin syndrome related to 5-HT3 rec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>476</th>\n",
       "      <td>HTR3A</td>\n",
       "      <td>blocker</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Description</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... of ondansetron and a selective blocking ag...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>477</th>\n",
       "      <td>LOC107987479</td>\n",
       "      <td>deficient</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Clinical Pharmacology</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... one enzyme (e.g., CYP2D6 genetic deficienc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>478</th>\n",
       "      <td>LOC107987479</td>\n",
       "      <td>deficient</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Other Section</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... one enzyme (e.g., CYP2D6 genetic deficienc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>479</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10028997</td>\n",
       "      <td>Neoplasm malignant</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>highly emetogenic cancer chemotherapy, includi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>480</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10028997</td>\n",
       "      <td>Neoplasm malignant</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... repeat courses of moderately emetogenic ca...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>481</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10028997</td>\n",
       "      <td>Neoplasm malignant</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... vomiting associated with highly emetogenic...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>482</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10028997</td>\n",
       "      <td>Neoplasm malignant</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... repeat courses of moderately emetogenic ca...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>483</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10047700</td>\n",
       "      <td>Vomiting</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... indicated for the prevention of nausea and...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>484</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10047700</td>\n",
       "      <td>Vomiting</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>nausea and vomiting associated with highly eme...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>485</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10047700</td>\n",
       "      <td>Vomiting</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>nausea and vomiting associated with initial an...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>486</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10047700</td>\n",
       "      <td>Vomiting</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>nausea and vomiting associated with radiothera...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>487</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10066962</td>\n",
       "      <td>Procedural nausea</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... indicated for the prevention of postoperat...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>488</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10066962</td>\n",
       "      <td>Procedural nausea</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>postoperative nausea and/or vomiting (...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>489</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10066963</td>\n",
       "      <td>Procedural vomiting</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>... postoperative nausea and/or vomiting.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>490</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>10066963</td>\n",
       "      <td>Procedural vomiting</td>\n",
       "      <td>Indications &amp; Usage</td>\n",
       "      <td>ANDA076183</td>\n",
       "      <td>20211124</td>\n",
       "      <td>https://dailymed.nlm.nih.gov/dailymed/lookup.c...</td>\n",
       "      <td>postoperative nausea and/or vomiting (1)</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        Biomarker         Relation [NID] MedDRA                    [PT] MedDRA                     Section       FDAID Label Revision Date                                             Source                                                Hit\n",
       "0           ABCB1        inhibitor                                                   Clinical Pharmacology   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... , trametinib is not an inhibitor of P-gp, ...\n",
       "1           ABCB1        inhibitor                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... , trametinib is not an inhibitor of P-gp, ...\n",
       "2           ABCG2        inhibitor                                                   Clinical Pharmacology   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... , trametinib is not an inhibitor of P-gp, ...\n",
       "3           ABCG2        inhibitor                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... , trametinib is not an inhibitor of P-gp, ...\n",
       "4             ALK      no mutation                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... or MEK inhibitor, and absence of EGFR muta...\n",
       "5             ALK      no mutation                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... or MEK inhibitor, and absence of EGFR muta...\n",
       "6             ALK    rearrangement                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... absence of EGFR mutation or ALK rearrangem...\n",
       "7             ALK    rearrangement                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... absence of EGFR mutation or ALK rearrangem...\n",
       "8            BRAF       activation                                                   Clinical Pharmacology   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... V600E mutations result in constitutive act...\n",
       "9            BRAF       activation                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... V600E mutations result in constitutive act...\n",
       "10           BRAF       diagnostic                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... retrospectively using an FDA-approved comp...\n",
       "11           BRAF       diagnostic                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... retrospectively using an FDA-approved comp...\n",
       "12           BRAF        inhibitor                                                   Clinical Pharmacology   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... mechanism of intrinsic resistance to BRAF ...\n",
       "13           BRAF        inhibitor                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... ; prior treatment with a BRAF inhibitor or...\n",
       "14           BRAF        inhibitor                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... ; prior treatment with a BRAF inhibitor or...\n",
       "15           BRAF        inhibitor                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... , no prior exposure to BRAF or MEK inhibit...\n",
       "16           BRAF        inhibitor                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... who received prior treatment with BRAF or ...\n",
       "17           BRAF        inhibitor                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... received prior treatment with a BRAF inhib...\n",
       "18           BRAF        inhibitor                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... mechanism of intrinsic resistance to BRAF ...\n",
       "19           BRAF        inhibitor                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... ; prior treatment with a BRAF inhibitor or...\n",
       "20           BRAF        inhibitor                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... ; prior treatment with a BRAF inhibitor or...\n",
       "21           BRAF        inhibitor                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... , no prior exposure to BRAF or MEK inhibit...\n",
       "22           BRAF        inhibitor                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... who received prior treatment with BRAF or ...\n",
       "23           BRAF        inhibitor                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... received prior treatment with a BRAF inhib...\n",
       "24           BRAF        inhibitor                                              SPL Patient Package Insert   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... who already have received a BRAF inhibitor...\n",
       "25           BRAF            level                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... than the ULN vs. ≤ ULN) and BRAF mutation ...\n",
       "26           BRAF            level                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... than the ULN vs. ≤ ULN) and BRAF mutation ...\n",
       "27           BRAF         mutation     10002240      Anaplastic thyroid cancer         Indications & Usage   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... with locally advanced or metastatic anapla...\n",
       "28           BRAF         mutation     10025650             Malignant melanoma            Adverse Reaction   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Adjuvant Treatment of BRAF V600E or V600K Muta...\n",
       "29           BRAF         mutation     10025650             Malignant melanoma            Adverse Reaction   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... 435 patients with Stage III melanoma with ...\n",
       "30           BRAF         mutation     10025650             Malignant melanoma              Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... metastatic (Stage IV) BRAF V600E or V600K ...\n",
       "31           BRAF         mutation     10025650             Malignant melanoma              Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... dabrafenib for the treatment of BRAF V600E...\n",
       "32           BRAF         mutation     10025650             Malignant melanoma              Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Adjuvant Treatment of BRAF V600E or V600K Muta...\n",
       "33           BRAF         mutation     10025650             Malignant melanoma              Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... enrolled patients with Stage III melanoma ...\n",
       "34           BRAF         mutation     10025650             Malignant melanoma               Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Adjuvant Treatment of BRAF V600E or V600K Muta...\n",
       "35           BRAF         mutation     10025650             Malignant melanoma               Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... adjuvant treatment of patients with melano...\n",
       "36           BRAF         mutation     10025650             Malignant melanoma               Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... tests for the detection of BRAF V600 mutat...\n",
       "37           BRAF         mutation     10025650             Malignant melanoma               Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Adjuvant Treatment of BRAF V600E or V600K Muta...\n",
       "38           BRAF         mutation     10025650             Malignant melanoma               Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... 435 patients with Stage III melanoma with ...\n",
       "39           BRAF         mutation     10025650             Malignant melanoma               Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... metastatic (Stage IV) BRAF V600E or V600K ...\n",
       "40           BRAF         mutation     10025650             Malignant melanoma               Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... dabrafenib for the treatment of BRAF V600E...\n",
       "41           BRAF         mutation     10025650             Malignant melanoma               Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Adjuvant Treatment of BRAF V600E or V600K Muta...\n",
       "42           BRAF         mutation     10025650             Malignant melanoma               Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... enrolled patients with Stage III melanoma ...\n",
       "43           BRAF         mutation     10028980                       Neoplasm              Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  BRAF V600E Mutation-Positive Unresectable or M...\n",
       "44           BRAF         mutation     10028980                       Neoplasm              Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... dabrafenib for the treatment of BRAF V600E...\n",
       "45           BRAF         mutation     10028980                       Neoplasm              Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... in adult patients with selected tumors wit...\n",
       "46           BRAF         mutation     10028980                       Neoplasm     Dosage & Administration   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Confirm the presence of BRAF V600E or V600K mu...\n",
       "47           BRAF         mutation     10028980                       Neoplasm     Dosage & Administration   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Confirm the presence of BRAF V600E mutation in...\n",
       "48           BRAF         mutation     10028980                       Neoplasm     Dosage & Administration   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Confirm the presence of BRAF V600E mutation in...\n",
       "49           BRAF         mutation     10028980                       Neoplasm     Dosage & Administration   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Confirm the presence of BRAF V600E mutation in...\n",
       "50           BRAF         mutation     10028980                       Neoplasm     Dosage & Administration   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... test for the detection of BRAF V600E mutat...\n",
       "51           BRAF         mutation     10028980                       Neoplasm         Indications & Usage   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... older with unresectable or metastatic soli...\n",
       "52           BRAF         mutation     10028980                       Neoplasm               Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  BRAF V600E Mutation-Positive Unresectable or M...\n",
       "53           BRAF         mutation     10028980                       Neoplasm               Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... older with unresectable or metastatic soli...\n",
       "54           BRAF         mutation     10028980                       Neoplasm               Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Confirm the presence of BRAF V600E or V600K mu...\n",
       "55           BRAF         mutation     10028980                       Neoplasm               Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Confirm the presence of BRAF V600E mutation in...\n",
       "56           BRAF         mutation     10028980                       Neoplasm               Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Confirm the presence of BRAF V600E mutation in...\n",
       "57           BRAF         mutation     10028980                       Neoplasm               Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Confirm the presence of BRAF V600E mutation in...\n",
       "58           BRAF         mutation     10028980                       Neoplasm               Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... test for the detection of BRAF V600E mutat...\n",
       "59           BRAF         mutation     10028980                       Neoplasm               Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  BRAF V600E Mutation-Positive Unresectable or M...\n",
       "60           BRAF         mutation     10028980                       Neoplasm               Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  BRAF V600E Mutation-Positive Unresectable or M...\n",
       "61           BRAF         mutation     10028980                       Neoplasm               Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... dabrafenib for the treatment of BRAF V600E...\n",
       "62           BRAF         mutation     10028980                       Neoplasm               Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... in adult patients with selected tumors wit...\n",
       "63           BRAF         mutation     10028980                       Neoplasm         Recent Major Change   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Indications and Usage, BRAF V600E Mutation-Pos...\n",
       "64           BRAF         mutation     10028980                       Neoplasm  Use In Specific Population   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  BRAF V600E Mutation-Positive Unresectable or M...\n",
       "65           BRAF         mutation     10028997             Neoplasm malignant            Adverse Reaction   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... study in adult patients with cancers with ...\n",
       "66           BRAF         mutation     10028997             Neoplasm malignant              Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... ) in patients with rare cancers with the B...\n",
       "67           BRAF         mutation     10028997             Neoplasm malignant               Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... study in adult patients with cancers with ...\n",
       "68           BRAF         mutation     10028997             Neoplasm malignant               Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... ) in patients with rare cancers with the B...\n",
       "69           BRAF         mutation     10061289            Metastatic neoplasm              Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... dabrafenib for the treatment of BRAF V600E...\n",
       "70           BRAF         mutation     10061289            Metastatic neoplasm         Indications & Usage   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  the treatment of patients with metastatic non-...\n",
       "71           BRAF         mutation     10061289            Metastatic neoplasm         Indications & Usage   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... patients with locally advanced or metastat...\n",
       "72           BRAF         mutation     10061289            Metastatic neoplasm         Indications & Usage   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... and older with unresectable or metastatic ...\n",
       "73           BRAF         mutation     10061289            Metastatic neoplasm         Indications & Usage   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...      BRAF V600E Mutation-Positive Metastatic NSCLC\n",
       "74           BRAF         mutation     10061289            Metastatic neoplasm               Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... dabrafenib for the treatment of BRAF V600E...\n",
       "75           BRAF         mutation     10061289            Metastatic neoplasm         Recent Major Change   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Indications and Usage, BRAF V600E Mutation-Pos...\n",
       "76           BRAF         mutation     10061873     Non-small cell lung cancer         Indications & Usage   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... treatment of patients with metastatic non-...\n",
       "77           BRAF         mutation                                                        Adverse Reaction   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... open-label trial of patients with BRAF V60...\n",
       "78           BRAF         mutation                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  BRAF V600E or V600K Mutation-Positive Unresect...\n",
       "79           BRAF         mutation                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... ) in 322 patients with BRAF V600E or V600K...\n",
       "80           BRAF         mutation                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Tumor tissue was evaluated for BRAF mutations ...\n",
       "81           BRAF         mutation                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  The distribution of BRAF V600 mutations was BR...\n",
       "82           BRAF         mutation                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  The distribution of BRAF V600 mutations was BR...\n",
       "83           BRAF         mutation                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... vs. ≤ ULN) and BRAF mutation subtype (V600...\n",
       "84           BRAF         mutation                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Randomization was stratified by BRAF mutation ...\n",
       "85           BRAF         mutation                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... unknown (1%); BRAF V600E mutation (91%), B...\n",
       "86           BRAF         mutation                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... mutation (91%), BRAF V600K mutation (9%); ...\n",
       "87           BRAF         mutation                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... IIIB vs. IIIC – and BRAF V600 mutation typ...\n",
       "88           BRAF         mutation                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... patients with retrospectively centrally co...\n",
       "89           BRAF         mutation                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  BRAF V600E Mutation-Positive Locally Advanced ...\n",
       "90           BRAF         mutation                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... trial in 40 patients with BRAF V600E or V6...\n",
       "91           BRAF         mutation                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... , and the distribution of BRAF V600 mutati...\n",
       "92           BRAF         mutation                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... based on local assessments of BRAF V600E m...\n",
       "93           BRAF         mutation                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... a central laboratory confirmed the BRAF V6...\n",
       "94           BRAF         mutation                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... that enrolled patients with a BRAF V600E m...\n",
       "95           BRAF         mutation                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  BRAF mutation status for enrollment was determ...\n",
       "96           BRAF         mutation                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... dabrafenib in patients with a BRAF V600E m...\n",
       "97           BRAF         mutation                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... patients with LGG with a BRAF V600E mutation.\n",
       "98           BRAF         mutation                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  For patients with BRAF V600E mutant LGG and HG...\n",
       "99           BRAF         mutation                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  BRAF V600E or V600K Mutation-Positive Unresect...\n",
       "100          BRAF         mutation                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... cancer (NSCLC) with BRAF V600E mutation as...\n",
       "101          BRAF         mutation                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  BRAF V600E Mutation-Positive Locally Advanced ...\n",
       "102          BRAF         mutation                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... cancer (ATC) with BRAF V600E mutation and ...\n",
       "103          BRAF         mutation                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... tests for the detection of BRAF V600E muta...\n",
       "104          BRAF         mutation                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... test for the detection of BRAF V600E mutat...\n",
       "105          BRAF         mutation                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... open-label trial of patients with BRAF V60...\n",
       "106          BRAF         mutation                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  BRAF V600E mutations result in constitutive ac...\n",
       "107          BRAF         mutation                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  BRAF V600E or V600K Mutation-Positive Unresect...\n",
       "108          BRAF         mutation                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... ) in 322 patients with BRAF V600E or V600K...\n",
       "109          BRAF         mutation                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Tumor tissue was evaluated for BRAF mutations ...\n",
       "110          BRAF         mutation                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  The distribution of BRAF V600 mutations was BR...\n",
       "111          BRAF         mutation                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  The distribution of BRAF V600 mutations was BR...\n",
       "112          BRAF         mutation                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... vs. ≤ ULN) and BRAF mutation subtype (V600...\n",
       "113          BRAF         mutation                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Randomization was stratified by BRAF mutation ...\n",
       "114          BRAF         mutation                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... unknown (1%); BRAF V600E mutation (91%), B...\n",
       "115          BRAF         mutation                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... mutation (91%), BRAF V600K mutation (9%); ...\n",
       "116          BRAF         mutation                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... IIIB vs. IIIC – and BRAF V600 mutation typ...\n",
       "117          BRAF         mutation                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... patients with retrospectively centrally co...\n",
       "118          BRAF         mutation                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  BRAF V600E Mutation-Positive Locally Advanced ...\n",
       "119          BRAF         mutation                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... trial in 40 patients with BRAF V600E or V6...\n",
       "120          BRAF         mutation                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... , and the distribution of BRAF V600 mutati...\n",
       "121          BRAF         mutation                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... based on local assessments of BRAF V600E m...\n",
       "122          BRAF         mutation                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... a central laboratory confirmed the BRAF V6...\n",
       "123          BRAF         mutation                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... that enrolled patients with a BRAF V600E m...\n",
       "124          BRAF         mutation                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  BRAF mutation status for enrollment was determ...\n",
       "125          BRAF         mutation                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... dabrafenib in patients with a BRAF V600E m...\n",
       "126          BRAF         mutation                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... patients with LGG with a BRAF V600E mutation.\n",
       "127          BRAF         mutation                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  For patients with BRAF V600E mutant LGG and HG...\n",
       "128          BRAF         mutation     10025650             Malignant melanoma     Dosage & Administration   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... tests for the detection of BRAF V600 mutat...\n",
       "129          BRAF         mutation     10025650             Malignant melanoma         Indications & Usage   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... adjuvant treatment of patients with melano...\n",
       "130          BRAF         mutation     10025650             Malignant melanoma         Indications & Usage   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Adjuvant Treatment of BRAF V600E or V600K Muta...\n",
       "131          BRAF         mutation     10027480  Metastatic malignant melanoma         Indications & Usage   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... treatment-naïve patients with unresectable...\n",
       "132          BRAF         mutation     10027480  Metastatic malignant melanoma         Indications & Usage   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... of patients with unresectable or metastati...\n",
       "133          BRAF         mutation     10027480  Metastatic malignant melanoma         Indications & Usage   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  BRAF V600E or V600K Mutation-Positive Unresect...\n",
       "134          BRAF         mutation     10027480  Metastatic malignant melanoma               Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... of patients with unresectable or metastati...\n",
       "135          BRAF         mutation                                                   Clinical Pharmacology   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  BRAF V600E mutations result in constitutive ac...\n",
       "136          BRAF         mutation                                                 Dosage & Administration   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... tests for the detection of BRAF V600E muta...\n",
       "137          BRAF         mutation                                                 Dosage & Administration   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... test for the detection of BRAF V600E mutat...\n",
       "138          BRAF         positive     10025650             Malignant melanoma            Adverse Reaction   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Adjuvant Treatment of BRAF V600E or V600K Muta...\n",
       "139          BRAF         positive     10025650             Malignant melanoma              Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... metastatic (Stage IV) BRAF V600E or V600K ...\n",
       "140          BRAF         positive     10025650             Malignant melanoma              Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... dabrafenib for the treatment of BRAF V600E...\n",
       "141          BRAF         positive     10025650             Malignant melanoma              Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Adjuvant Treatment of BRAF V600E or V600K Muta...\n",
       "142          BRAF         positive     10025650             Malignant melanoma         Indications & Usage   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Adjuvant Treatment of BRAF V600E or V600K Muta...\n",
       "143          BRAF         positive     10025650             Malignant melanoma               Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Adjuvant Treatment of BRAF V600E or V600K Muta...\n",
       "144          BRAF         positive     10025650             Malignant melanoma               Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Adjuvant Treatment of BRAF V600E or V600K Muta...\n",
       "145          BRAF         positive     10025650             Malignant melanoma               Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... metastatic (Stage IV) BRAF V600E or V600K ...\n",
       "146          BRAF         positive     10025650             Malignant melanoma               Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... dabrafenib for the treatment of BRAF V600E...\n",
       "147          BRAF         positive     10025650             Malignant melanoma               Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Adjuvant Treatment of BRAF V600E or V600K Muta...\n",
       "148          BRAF         positive     10027480  Metastatic malignant melanoma         Indications & Usage   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  BRAF V600E or V600K Mutation-Positive Unresect...\n",
       "149          BRAF         positive     10028980                       Neoplasm              Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  BRAF V600E Mutation-Positive Unresectable or M...\n",
       "150          BRAF         positive     10028980                       Neoplasm              Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... dabrafenib for the treatment of BRAF V600E...\n",
       "151          BRAF         positive     10028980                       Neoplasm               Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  BRAF V600E Mutation-Positive Unresectable or M...\n",
       "152          BRAF         positive     10028980                       Neoplasm               Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  BRAF V600E Mutation-Positive Unresectable or M...\n",
       "153          BRAF         positive     10028980                       Neoplasm               Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  BRAF V600E Mutation-Positive Unresectable or M...\n",
       "154          BRAF         positive     10028980                       Neoplasm               Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... dabrafenib for the treatment of BRAF V600E...\n",
       "155          BRAF         positive     10028980                       Neoplasm         Recent Major Change   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Indications and Usage, BRAF V600E Mutation-Pos...\n",
       "156          BRAF         positive     10028980                       Neoplasm  Use In Specific Population   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  BRAF V600E Mutation-Positive Unresectable or M...\n",
       "157          BRAF         positive     10061289            Metastatic neoplasm              Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... dabrafenib for the treatment of BRAF V600E...\n",
       "158          BRAF         positive     10061289            Metastatic neoplasm         Indications & Usage   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...      BRAF V600E Mutation-Positive Metastatic NSCLC\n",
       "159          BRAF         positive     10061289            Metastatic neoplasm               Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... dabrafenib for the treatment of BRAF V600E...\n",
       "160          BRAF         positive     10061289            Metastatic neoplasm         Recent Major Change   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Indications and Usage, BRAF V600E Mutation-Pos...\n",
       "161          BRAF         positive                                                        Adverse Reaction   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... open-label trial of patients with BRAF V60...\n",
       "162          BRAF         positive                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  BRAF V600E or V600K Mutation-Positive Unresect...\n",
       "163          BRAF         positive                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... ) in 322 patients with BRAF V600E or V600K...\n",
       "164          BRAF         positive                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... patients with retrospectively centrally co...\n",
       "165          BRAF         positive                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  BRAF V600E Mutation-Positive Locally Advanced ...\n",
       "166          BRAF         positive                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... trial in 40 patients with BRAF V600E or V6...\n",
       "167          BRAF         positive                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  BRAF V600E or V600K Mutation-Positive Unresect...\n",
       "168          BRAF         positive                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  BRAF V600E Mutation-Positive Locally Advanced ...\n",
       "169          BRAF         positive                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... open-label trial of patients with BRAF V60...\n",
       "170          BRAF         positive                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  BRAF V600E or V600K Mutation-Positive Unresect...\n",
       "171          BRAF         positive                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... ) in 322 patients with BRAF V600E or V600K...\n",
       "172          BRAF         positive                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... patients with retrospectively centrally co...\n",
       "173          BRAF         positive                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  BRAF V600E Mutation-Positive Locally Advanced ...\n",
       "174          BRAF         positive                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... trial in 40 patients with BRAF V600E or V6...\n",
       "175        CYP1A2        inhibitor                                                   Clinical Pharmacology   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... , but is not an inhibitor of CYP1A2, CYP2A...\n",
       "176        CYP1A2        inhibitor                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... , but is not an inhibitor of CYP1A2, CYP2A...\n",
       "177        CYP2A6        inhibitor                                                   Clinical Pharmacology   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... , but is not an inhibitor of CYP1A2, CYP2A...\n",
       "178        CYP2A6        inhibitor                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... , but is not an inhibitor of CYP1A2, CYP2A...\n",
       "179        CYP2B6        inhibitor                                                   Clinical Pharmacology   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... , but is not an inhibitor of CYP1A2, CYP2A...\n",
       "180        CYP2B6        inhibitor                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... , but is not an inhibitor of CYP1A2, CYP2A...\n",
       "181        CYP2C8        inhibitor                                                   Clinical Pharmacology   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... studies, trametinib is an inhibitor of CYP...\n",
       "182        CYP2C8        inhibitor                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... studies, trametinib is an inhibitor of CYP...\n",
       "183        CYP2C9        inhibitor                                                   Clinical Pharmacology   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... , but is not an inhibitor of CYP1A2, CYP2A...\n",
       "184        CYP2C9        inhibitor                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... , but is not an inhibitor of CYP1A2, CYP2A...\n",
       "185       CYP2C19        inhibitor                                                   Clinical Pharmacology   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... , but is not an inhibitor of CYP1A2, CYP2A...\n",
       "186       CYP2C19        inhibitor                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... , but is not an inhibitor of CYP1A2, CYP2A...\n",
       "187        CYP3A4          inducer                                                   Clinical Pharmacology   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...       Trametinib is an inducer of CYP3A in vitro .\n",
       "188        CYP3A4          inducer                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...       Trametinib is an inducer of CYP3A in vitro .\n",
       "189         EPHB2  phosphorylation                                                   Clinical Pharmacology   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... biomarkers, including inhibition of phosph...\n",
       "190         EPHB2  phosphorylation                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... biomarkers, including inhibition of phosph...\n",
       "191          GOT1         increase     10020635                 Hyperglycaemia            Adverse Reaction   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... lymphopenia, increased ALT, increased AST,...\n",
       "192          GOT1         increase     10020635                 Hyperglycaemia               Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... lymphopenia, increased ALT, increased AST,...\n",
       "193          GOT1         increase                                                        Adverse Reaction   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... ), increased ALT and increased AST (each n...\n",
       "194          GOT1         increase                                                        Adverse Reaction   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... , increased ALT, and increased AST (each n...\n",
       "195          GOT1         increase                                                        Adverse Reaction   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...                                      Increased AST\n",
       "196          GOT1         increase                                                        Adverse Reaction   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...                                      Increased AST\n",
       "197          GOT1         increase                                                        Adverse Reaction   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...                                      Increased AST\n",
       "198          GOT1         increase                                                        Adverse Reaction   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...                                      Increased AST\n",
       "199          GOT1         increase                                                        Adverse Reaction   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... increased (6%), AST increased (4.2%) and e...\n",
       "200          GOT1         increase                                                        Adverse Reaction   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...                                      Increased AST\n",
       "201          GOT1         increase                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... ), increased ALT and increased AST (each n...\n",
       "202          GOT1         increase                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... , increased ALT, and increased AST (each n...\n",
       "203          GOT1         increase                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...                                      Increased AST\n",
       "204          GOT1         increase                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...                                      Increased AST\n",
       "205          GOT1         increase                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...                                      Increased AST\n",
       "206          GOT1         increase                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...                                      Increased AST\n",
       "207          GOT1         increase                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... increased (6%), AST increased (4.2%) and e...\n",
       "208          GOT1         increase                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...                                      Increased AST\n",
       "209          GOT1            level                                                   Clinical Pharmacology   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... impairment defined by bilirubin and AST le...\n",
       "210          GOT1            level     10019670      Hepatic function abnormal               Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... bilirubin > 1x to 1.5x ULN and any AST) he...\n",
       "211          GOT1            level     10019670      Hepatic function abnormal               Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... bilirubin > 3x to 10x ULN and any AST) hep...\n",
       "212          GOT1            level     10019670      Hepatic function abnormal  Use In Specific Population   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... bilirubin > 1x to 1.5x ULN and any AST) he...\n",
       "213          GOT1            level     10019670      Hepatic function abnormal  Use In Specific Population   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... bilirubin > 3x to 10x ULN and any AST) hep...\n",
       "214          GOT1            level                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... ) and aspartate aminotransferase (AST) > U...\n",
       "215          GOT1            level                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... bilirubin > 1.5x to 3x ULN and any AST) or...\n",
       "216          GOT1            level                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... impairment defined by bilirubin and AST le...\n",
       "217          GOT1            level                                              Use In Specific Population   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... ) and aspartate aminotransferase (AST) > U...\n",
       "218          GOT1            level                                              Use In Specific Population   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... bilirubin > 1.5x to 3x ULN and any AST) or...\n",
       "219           GPT         increase                                                        Adverse Reaction   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...           Increased alanine aminotransferase (ALT)\n",
       "220           GPT         increase                                                        Adverse Reaction   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... n = 4), increased ALT and increased AST (e...\n",
       "221           GPT         increase                                                        Adverse Reaction   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... neutropenia, thrombocytopenia, increased A...\n",
       "222           GPT         increase                                                        Adverse Reaction   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...                                      Increased ALT\n",
       "223           GPT         increase                                                        Adverse Reaction   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...                                      Increased ALT\n",
       "224           GPT         increase                                                        Adverse Reaction   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...                                      Increased ALT\n",
       "225           GPT         increase                                                        Adverse Reaction   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...                                      Increased ALT\n",
       "226           GPT         increase                                                        Adverse Reaction   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... > 3% of patients included ALT increased (6...\n",
       "227           GPT         increase                                                        Adverse Reaction   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...                                      Increased ALT\n",
       "228           GPT         increase                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...           Increased alanine aminotransferase (ALT)\n",
       "229           GPT         increase                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... n = 4), increased ALT and increased AST (e...\n",
       "230           GPT         increase                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... neutropenia, thrombocytopenia, increased A...\n",
       "231           GPT         increase                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...                                      Increased ALT\n",
       "232           GPT         increase                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...                                      Increased ALT\n",
       "233           GPT         increase                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...                                      Increased ALT\n",
       "234           GPT         increase                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...                                      Increased ALT\n",
       "235           GPT         increase                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... > 3% of patients included ALT increased (6...\n",
       "236           GPT         increase                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...                                      Increased ALT\n",
       "237         KCNK3        inhibitor                                                   Clinical Pharmacology   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... , trametinib is not an inhibitor of P-gp, ...\n",
       "238         KCNK3        inhibitor                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... , trametinib is not an inhibitor of P-gp, ...\n",
       "239        MAP2K1       activation                                                   Clinical Pharmacology   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... (MEK1) and MEK2 activation and of MEK1 and...\n",
       "240        MAP2K1       activation                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... (MEK1) and MEK2 activation and of MEK1 and...\n",
       "241        MAP2K2       activation                                                   Clinical Pharmacology   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... 1 (MEK1) and MEK2 activation and of MEK1 a...\n",
       "242        MAP2K2       activation                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... 1 (MEK1) and MEK2 activation and of MEK1 a...\n",
       "243        MAP2K7        inhibitor                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... with a BRAF inhibitor or MEK inhibitor was...\n",
       "244        MAP2K7        inhibitor                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... prior exposure to BRAF or MEK inhibitor, a...\n",
       "245        MAP2K7        inhibitor                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... prior treatment with BRAF or MEK inhibitor...\n",
       "246        MAP2K7        inhibitor                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... with a BRAF inhibitor or MEK inhibitor was...\n",
       "247        MAP2K7        inhibitor                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... prior exposure to BRAF or MEK inhibitor, a...\n",
       "248        MAP2K7        inhibitor                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... prior treatment with BRAF or MEK inhibitor...\n",
       "249        MAP2K7      no mutation                                                          Clinical Study   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... prior exposure to BRAF or MEK inhibitor, a...\n",
       "250        MAP2K7      no mutation                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... prior exposure to BRAF or MEK inhibitor, a...\n",
       "251         MAPK1  phosphorylation                                                   Clinical Pharmacology   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... biomarkers, including inhibition of phosph...\n",
       "252         MAPK1  phosphorylation                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... biomarkers, including inhibition of phosph...\n",
       "253         MAPK3        inhibitor                                                   Clinical Pharmacology   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Trametinib is a reversible inhibitor of mitoge...\n",
       "254         MAPK3        inhibitor                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Trametinib is a reversible inhibitor of mitoge...\n",
       "255          PAK2         increase                                                   Clinical Pharmacology   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... cell proliferation), and increases in p27 ...\n",
       "256          PAK2         increase                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... cell proliferation), and increases in p27 ...\n",
       "257       SLC22A6        inhibitor                                                   Clinical Pharmacology   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... , trametinib is not an inhibitor of P-gp, ...\n",
       "258       SLC22A6        inhibitor                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... , trametinib is not an inhibitor of P-gp, ...\n",
       "259       SLCO1B1        inhibitor                                                   Clinical Pharmacology   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... , trametinib is not an inhibitor of P-gp, ...\n",
       "260       SLCO1B1        inhibitor                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... , trametinib is not an inhibitor of P-gp, ...\n",
       "261       SLCO1B3        inhibitor                                                   Clinical Pharmacology   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... , trametinib is not an inhibitor of P-gp, ...\n",
       "262       SLCO1B3        inhibitor                                                           Other Section   NDA204114            20220622  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... , trametinib is not an inhibitor of P-gp, ...\n",
       "263        CYP3A4          inducer                                                   Clinical Pharmacology  ANDA076183            20211006  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  CYP 3A4 Inducers: Ondansetron elimination may ...\n",
       "264        CYP3A4          inducer                                                   Clinical Pharmacology  ANDA076183            20211006  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... epileptic patients maintained chronically ...\n",
       "265        CYP3A4          inducer                                                        Drug Interaction  ANDA076183            20211006  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  In patients treated with potent inducers of CY...\n",
       "266        CYP4F3          inducer                                                   Clinical Pharmacology  ANDA076183            20211006  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... elimination may be affected by cytochrome ...\n",
       "267        CYP4F3        inhibitor                                                        Drug Interaction  ANDA076183            20211006  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... itself appear to induce or inhibit the cyt...\n",
       "268         HTR3A       antagonist     10020751               Hypersensitivity      Warning And Precaution  ANDA076183            20211006  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... in patients who have exhibited hypersensit...\n",
       "269         HTR3A       antagonist     10040108             Serotonin syndrome      Warning And Precaution  ANDA076183            20211006  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  The majority of reports of serotonin syndrome ...\n",
       "270         HTR3A       antagonist                                                        Drug Interaction  ANDA076183            20211006  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... following the concomitant use of 5-HT3 rec...\n",
       "271         HTR3A       antagonist                                                        SPL Unclassified  ANDA076183            20211006  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Ondansetron tablets are 5-HT3 receptor antagon...\n",
       "272         HTR3A       antagonist                                                        SPL Unclassified  ANDA076183            20211006  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Serotonin syndrome: Reported with 5-HT3 recept...\n",
       "273         HTR3A       antagonist                                                  Warning And Precaution  ANDA076183            20211006  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... syndrome has been reported with 5-HT3 rece...\n",
       "274         HTR3A       antagonist                                                  Warning And Precaution  ANDA076183            20211006  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... of serotonin syndrome related to 5-HT3 rec...\n",
       "275         HTR3A          blocker                                                             Description  ANDA076183            20211006  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... of ondansetron and a selective blocking ag...\n",
       "276                                    10028997             Neoplasm malignant         Indications & Usage  ANDA076183            20211006  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  highly emetogenic cancer chemotherapy, includi...\n",
       "277                                    10028997             Neoplasm malignant         Indications & Usage  ANDA076183            20211006  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... repeat courses of moderately emetogenic ca...\n",
       "278                                    10047700                       Vomiting         Indications & Usage  ANDA076183            20211006  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... indicated for the prevention of nausea and...\n",
       "279                                    10066962              Procedural nausea         Indications & Usage  ANDA076183            20211006  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... indicated for the prevention of postoperat...\n",
       "280                                    10066963            Procedural vomiting         Indications & Usage  ANDA076183            20211006  https://dailymed.nlm.nih.gov/dailymed/lookup.c...          ... postoperative nausea and/or vomiting.\n",
       "281        CYP2D6        deficient                                                   Clinical Pharmacology  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... one enzyme (e.g., CYP2D6 genetic deficienc...\n",
       "282        CYP2D6        deficient                                                           Other Section  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... one enzyme (e.g., CYP2D6 genetic deficienc...\n",
       "283        CYP2D7        deficient                                                   Clinical Pharmacology  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... one enzyme (e.g., CYP2D6 genetic deficienc...\n",
       "284        CYP2D7        deficient                                                           Other Section  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... one enzyme (e.g., CYP2D6 genetic deficienc...\n",
       "285        CYP3A4          inducer                                                   Clinical Pharmacology  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... epileptic patients maintained chronically ...\n",
       "286        CYP3A4          inducer                                                           Other Section  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... epileptic patients maintained chronically ...\n",
       "287        CYP3A4          inducer                                                           Other Section  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  In patients treated with potent inducers of CY...\n",
       "288        CYP3A4          inducer                                                              Precaution  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  In patients treated with potent inducers of CY...\n",
       "289        CYP4F3          inducer                                                   Clinical Pharmacology  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... elimination may be affected by cytochrome ...\n",
       "290        CYP4F3          inducer                                                           Other Section  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... elimination may be affected by cytochrome ...\n",
       "291        CYP4F3        inhibitor                                                           Other Section  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... itself appear to induce or inhibit the cyt...\n",
       "292        CYP4F3        inhibitor                                                              Precaution  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... itself appear to induce or inhibit the cyt...\n",
       "293         HTR3A       antagonist     10020751               Hypersensitivity                     Warning  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... in patients who have exhibited hypersensit...\n",
       "294         HTR3A       antagonist     10040108             Serotonin syndrome                     Warning  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  The majority of reports of serotonin syndrome ...\n",
       "295         HTR3A       antagonist                                                   Clinical Pharmacology  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Ondansetron is a selective 5-HT3 receptor anta...\n",
       "296         HTR3A       antagonist                                                   Clinical Pharmacology  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... or pretreatment with a serotonin 5-HT3 rec...\n",
       "297         HTR3A       antagonist                                                           Other Section  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Ondansetron is a selective 5-HT3 receptor anta...\n",
       "298         HTR3A       antagonist                                                           Other Section  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... or pretreatment with a serotonin 5-HT3 rec...\n",
       "299         HTR3A       antagonist                                                           Other Section  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... following the concomitant use of 5-HT3 rec...\n",
       "300         HTR3A       antagonist                                                              Precaution  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... following the concomitant use of 5-HT3 rec...\n",
       "301         HTR3A       antagonist                                                                 Warning  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... syndrome has been reported with 5-HT3 rece...\n",
       "302         HTR3A       antagonist                                                                 Warning  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... of serotonin syndrome related to 5-HT3 rec...\n",
       "303         HTR3A          blocker                                                             Description  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... of ondansetron and a selective blocking ag...\n",
       "304  LOC107987479        deficient                                                   Clinical Pharmacology  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... one enzyme (e.g., CYP2D6 genetic deficienc...\n",
       "305  LOC107987479        deficient                                                           Other Section  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... one enzyme (e.g., CYP2D6 genetic deficienc...\n",
       "306                                    10028813                         Nausea         Indications & Usage  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... there is little expectation that nausea an...\n",
       "307                                    10028813                         Nausea         Indications & Usage  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  In patients where nausea and/or vomiting must ...\n",
       "308                                    10028997             Neoplasm malignant         Indications & Usage  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... vomiting associated with highly emetogenic...\n",
       "309                                    10028997             Neoplasm malignant         Indications & Usage  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... repeat courses of moderately emetogenic ca...\n",
       "310                                    10047700                       Vomiting         Indications & Usage  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Prevention of nausea and vomiting associated w...\n",
       "311                                    10047700                       Vomiting         Indications & Usage  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Prevention of nausea and vomiting associated w...\n",
       "312                                    10047700                       Vomiting         Indications & Usage  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Prevention of nausea and vomiting associated w...\n",
       "313                                    10047700                       Vomiting         Indications & Usage  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... that nausea and/or vomiting will occur pos...\n",
       "314                                    10047700                       Vomiting         Indications & Usage  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... where nausea and/or vomiting must be avoid...\n",
       "315                                    10066962              Procedural nausea         Indications & Usage  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Prevention of postoperative nausea and/or vomi...\n",
       "316                                    10066962              Procedural nausea         Indications & Usage  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... even where the incidence of postoperative ...\n",
       "317                                    10066963            Procedural vomiting         Indications & Usage  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...          ... postoperative nausea and/or vomiting.\n",
       "318                                    10066963            Procedural vomiting         Indications & Usage  ANDA076183            20190429  https://dailymed.nlm.nih.gov/dailymed/lookup.c...   ... postoperative nausea and/or vomiting is low.\n",
       "319        CYP2D6        deficient                                                   Clinical Pharmacology  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... one enzyme (e.g., CYP2D6 genetic deficienc...\n",
       "320        CYP2D6        deficient                                                           Other Section  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... one enzyme (e.g., CYP2D6 genetic deficienc...\n",
       "321        CYP2D7        deficient                                                   Clinical Pharmacology  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... one enzyme (e.g., CYP2D6 genetic deficienc...\n",
       "322        CYP2D7        deficient                                                           Other Section  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... one enzyme (e.g., CYP2D6 genetic deficienc...\n",
       "323        CYP3A4          inducer                                                   Clinical Pharmacology  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  CYP 3A4 Inducers: Ondansetron elimination may ...\n",
       "324        CYP3A4          inducer                                                   Clinical Pharmacology  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... epileptic patients maintained chronically ...\n",
       "325        CYP3A4          inducer                                                        Drug Interaction  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  In patients treated with potent inducers of CY...\n",
       "326        CYP3A4          inducer                                                           Other Section  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  In patients treated with potent inducers of CY...\n",
       "327        CYP3A4          inducer                                                           Other Section  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  CYP 3A4 Inducers: Ondansetron elimination may ...\n",
       "328        CYP3A4          inducer                                                           Other Section  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... epileptic patients maintained chronically ...\n",
       "329        CYP4F3          inducer                                                   Clinical Pharmacology  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... elimination may be affected by cytochrome ...\n",
       "330        CYP4F3          inducer                                                           Other Section  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... elimination may be affected by cytochrome ...\n",
       "331        CYP4F3        inhibitor                                                        Drug Interaction  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... itself appear to induce or inhibit the cyt...\n",
       "332        CYP4F3        inhibitor                                                           Other Section  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... itself appear to induce or inhibit the cyt...\n",
       "333         HTR3A       antagonist     10020751               Hypersensitivity               Other Section  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... in patients who have exhibited hypersensit...\n",
       "334         HTR3A       antagonist     10020751               Hypersensitivity      Warning And Precaution  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... in patients who have exhibited hypersensit...\n",
       "335         HTR3A       antagonist     10040108             Serotonin syndrome               Other Section  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  The majority of reports of serotonin syndrome ...\n",
       "336         HTR3A       antagonist     10040108             Serotonin syndrome      Warning And Precaution  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  The majority of reports of serotonin syndrome ...\n",
       "337         HTR3A       antagonist                                                   Clinical Pharmacology  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Ondansetron is a selective 5-HT3 receptor anta...\n",
       "338         HTR3A       antagonist                                                        Drug Interaction  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... following the concomitant use of 5-HT3 rec...\n",
       "339         HTR3A       antagonist                                                     Indications & Usage  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Ondansetron tablets are 5-HT3 receptor antagon...\n",
       "340         HTR3A       antagonist                                                           Other Section  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... syndrome has been reported with 5-HT3 rece...\n",
       "341         HTR3A       antagonist                                                           Other Section  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... of serotonin syndrome related to 5-HT3 rec...\n",
       "342         HTR3A       antagonist                                                           Other Section  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... following the concomitant use of 5-HT3 rec...\n",
       "343         HTR3A       antagonist                                                           Other Section  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Ondansetron is a selective 5-HT3 receptor anta...\n",
       "344         HTR3A       antagonist                                                  Warning And Precaution  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Serotonin Syndrome : Reported with 5-HT3 recep...\n",
       "345         HTR3A       antagonist                                                  Warning And Precaution  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... syndrome has been reported with 5-HT3 rece...\n",
       "346         HTR3A       antagonist                                                  Warning And Precaution  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... of serotonin syndrome related to 5-HT3 rec...\n",
       "347         HTR3A          blocker                                                             Description  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... of ondansetron and a selective blocking ag...\n",
       "348  LOC107987479        deficient                                                   Clinical Pharmacology  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... one enzyme (e.g., CYP2D6 genetic deficienc...\n",
       "349  LOC107987479        deficient                                                           Other Section  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... one enzyme (e.g., CYP2D6 genetic deficienc...\n",
       "350                                    10028997             Neoplasm malignant         Indications & Usage  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  highly emetogenic cancer chemotherapy, includi...\n",
       "351                                    10028997             Neoplasm malignant         Indications & Usage  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... repeat courses of moderately emetogenic ca...\n",
       "352                                    10028997             Neoplasm malignant         Indications & Usage  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... vomiting associated with highly emetogenic...\n",
       "353                                    10028997             Neoplasm malignant         Indications & Usage  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... repeat courses of moderately emetogenic ca...\n",
       "354                                    10047700                       Vomiting         Indications & Usage  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... indicated for the prevention of nausea and...\n",
       "355                                    10047700                       Vomiting         Indications & Usage  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  nausea and vomiting associated with highly eme...\n",
       "356                                    10047700                       Vomiting         Indications & Usage  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  nausea and vomiting associated with initial an...\n",
       "357                                    10047700                       Vomiting         Indications & Usage  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  nausea and vomiting associated with radiothera...\n",
       "358                                    10066962              Procedural nausea         Indications & Usage  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... indicated for the prevention of postoperat...\n",
       "359                                    10066962              Procedural nausea         Indications & Usage  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...          postoperative nausea and/or vomiting (...\n",
       "360                                    10066963            Procedural vomiting         Indications & Usage  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...          ... postoperative nausea and/or vomiting.\n",
       "361                                    10066963            Procedural vomiting         Indications & Usage  ANDA076183            20220503  https://dailymed.nlm.nih.gov/dailymed/lookup.c...           postoperative nausea and/or vomiting (1)\n",
       "362        CYP2D6        deficient                                                   Clinical Pharmacology  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... one enzyme (e.g., CYP2D6 genetic deficienc...\n",
       "363        CYP2D6        deficient                                                           Other Section  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... one enzyme (e.g., CYP2D6 genetic deficienc...\n",
       "364        CYP2D7        deficient                                                   Clinical Pharmacology  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... one enzyme (e.g., CYP2D6 genetic deficienc...\n",
       "365        CYP2D7        deficient                                                           Other Section  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... one enzyme (e.g., CYP2D6 genetic deficienc...\n",
       "366        CYP3A4          inducer                                                   Clinical Pharmacology  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  CYP 3A4 Inducers: Ondansetron elimination may ...\n",
       "367        CYP3A4          inducer                                                   Clinical Pharmacology  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... epileptic patients maintained chronically ...\n",
       "368        CYP3A4          inducer                                                        Drug Interaction  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  In patients treated with potent inducers of CY...\n",
       "369        CYP3A4          inducer                                                           Other Section  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  In patients treated with potent inducers of CY...\n",
       "370        CYP3A4          inducer                                                           Other Section  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  CYP 3A4 Inducers: Ondansetron elimination may ...\n",
       "371        CYP3A4          inducer                                                           Other Section  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... epileptic patients maintained chronically ...\n",
       "372        CYP4F3          inducer                                                   Clinical Pharmacology  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... elimination may be affected by cytochrome ...\n",
       "373        CYP4F3          inducer                                                           Other Section  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... elimination may be affected by cytochrome ...\n",
       "374        CYP4F3        inhibitor                                                        Drug Interaction  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... itself appear to induce or inhibit the cyt...\n",
       "375        CYP4F3        inhibitor                                                           Other Section  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... itself appear to induce or inhibit the cyt...\n",
       "376         HTR3A       antagonist     10020751               Hypersensitivity               Other Section  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... in patients who have exhibited hypersensit...\n",
       "377         HTR3A       antagonist     10020751               Hypersensitivity      Warning And Precaution  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... in patients who have exhibited hypersensit...\n",
       "378         HTR3A       antagonist     10040108             Serotonin syndrome               Other Section  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  The majority of reports of serotonin syndrome ...\n",
       "379         HTR3A       antagonist     10040108             Serotonin syndrome      Warning And Precaution  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  The majority of reports of serotonin syndrome ...\n",
       "380         HTR3A       antagonist                                                   Clinical Pharmacology  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Ondansetron is a selective 5-HT3 receptor anta...\n",
       "381         HTR3A       antagonist                                                        Drug Interaction  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... following the concomitant use of 5-HT3 rec...\n",
       "382         HTR3A       antagonist                                                     Indications & Usage  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Ondansetron tablets are 5-HT3 receptor antagon...\n",
       "383         HTR3A       antagonist                                                           Other Section  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... syndrome has been reported with 5-HT3 rece...\n",
       "384         HTR3A       antagonist                                                           Other Section  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... of serotonin syndrome related to 5-HT3 rec...\n",
       "385         HTR3A       antagonist                                                           Other Section  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... following the concomitant use of 5-HT3 rec...\n",
       "386         HTR3A       antagonist                                                           Other Section  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Ondansetron is a selective 5-HT3 receptor anta...\n",
       "387         HTR3A       antagonist                                                  Warning And Precaution  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Serotonin Syndrome : Reported with 5-HT3 recep...\n",
       "388         HTR3A       antagonist                                                  Warning And Precaution  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... syndrome has been reported with 5-HT3 rece...\n",
       "389         HTR3A       antagonist                                                  Warning And Precaution  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... of serotonin syndrome related to 5-HT3 rec...\n",
       "390         HTR3A          blocker                                                             Description  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... of ondansetron and a selective blocking ag...\n",
       "391  LOC107987479        deficient                                                   Clinical Pharmacology  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... one enzyme (e.g., CYP2D6 genetic deficienc...\n",
       "392  LOC107987479        deficient                                                           Other Section  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... one enzyme (e.g., CYP2D6 genetic deficienc...\n",
       "393                                    10028997             Neoplasm malignant         Indications & Usage  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  highly emetogenic cancer chemotherapy, includi...\n",
       "394                                    10028997             Neoplasm malignant         Indications & Usage  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... repeat courses of moderately emetogenic ca...\n",
       "395                                    10028997             Neoplasm malignant         Indications & Usage  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... vomiting associated with highly emetogenic...\n",
       "396                                    10028997             Neoplasm malignant         Indications & Usage  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... repeat courses of moderately emetogenic ca...\n",
       "397                                    10047700                       Vomiting         Indications & Usage  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... indicated for the prevention of nausea and...\n",
       "398                                    10047700                       Vomiting         Indications & Usage  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  nausea and vomiting associated with highly eme...\n",
       "399                                    10047700                       Vomiting         Indications & Usage  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  nausea and vomiting associated with initial an...\n",
       "400                                    10047700                       Vomiting         Indications & Usage  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  nausea and vomiting associated with radiothera...\n",
       "401                                    10066962              Procedural nausea         Indications & Usage  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... indicated for the prevention of postoperat...\n",
       "402                                    10066962              Procedural nausea         Indications & Usage  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...          postoperative nausea and/or vomiting (...\n",
       "403                                    10066963            Procedural vomiting         Indications & Usage  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...          ... postoperative nausea and/or vomiting.\n",
       "404                                    10066963            Procedural vomiting         Indications & Usage  ANDA076183            20210525  https://dailymed.nlm.nih.gov/dailymed/lookup.c...           postoperative nausea and/or vomiting (1)\n",
       "405        CYP2D6        deficient                                                   Clinical Pharmacology  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... one enzyme (e.g., CYP2D6 genetic deficienc...\n",
       "406        CYP2D6        deficient                                                           Other Section  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... one enzyme (e.g., CYP2D6 genetic deficienc...\n",
       "407        CYP2D7        deficient                                                   Clinical Pharmacology  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... one enzyme (e.g., CYP2D6 genetic deficienc...\n",
       "408        CYP2D7        deficient                                                           Other Section  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... one enzyme (e.g., CYP2D6 genetic deficienc...\n",
       "409        CYP3A4          inducer                                                   Clinical Pharmacology  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  CYP 3A4 Inducers: Ondansetron elimination may ...\n",
       "410        CYP3A4          inducer                                                   Clinical Pharmacology  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... epileptic patients maintained chronically ...\n",
       "411        CYP3A4          inducer                                                        Drug Interaction  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  In patients treated with potent inducers of CY...\n",
       "412        CYP3A4          inducer                                                           Other Section  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  In patients treated with potent inducers of CY...\n",
       "413        CYP3A4          inducer                                                           Other Section  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  CYP 3A4 Inducers: Ondansetron elimination may ...\n",
       "414        CYP3A4          inducer                                                           Other Section  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... epileptic patients maintained chronically ...\n",
       "415        CYP4F3          inducer                                                   Clinical Pharmacology  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... elimination may be affected by cytochrome ...\n",
       "416        CYP4F3          inducer                                                           Other Section  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... elimination may be affected by cytochrome ...\n",
       "417        CYP4F3        inhibitor                                                        Drug Interaction  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... itself appear to induce or inhibit the cyt...\n",
       "418        CYP4F3        inhibitor                                                           Other Section  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... itself appear to induce or inhibit the cyt...\n",
       "419         HTR3A       antagonist     10020751               Hypersensitivity               Other Section  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... in patients who have exhibited hypersensit...\n",
       "420         HTR3A       antagonist     10020751               Hypersensitivity      Warning And Precaution  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... in patients who have exhibited hypersensit...\n",
       "421         HTR3A       antagonist     10040108             Serotonin syndrome               Other Section  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  The majority of reports of serotonin syndrome ...\n",
       "422         HTR3A       antagonist     10040108             Serotonin syndrome      Warning And Precaution  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  The majority of reports of serotonin syndrome ...\n",
       "423         HTR3A       antagonist                                                   Clinical Pharmacology  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Ondansetron is a selective 5-HT3 receptor anta...\n",
       "424         HTR3A       antagonist                                                        Drug Interaction  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... following the concomitant use of 5-HT3 rec...\n",
       "425         HTR3A       antagonist                                                     Indications & Usage  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Ondansetron tablets are 5-HT3 receptor antagon...\n",
       "426         HTR3A       antagonist                                                           Other Section  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... syndrome has been reported with 5-HT3 rece...\n",
       "427         HTR3A       antagonist                                                           Other Section  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... of serotonin syndrome related to 5-HT3 rec...\n",
       "428         HTR3A       antagonist                                                           Other Section  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... following the concomitant use of 5-HT3 rec...\n",
       "429         HTR3A       antagonist                                                           Other Section  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Ondansetron is a selective 5-HT3 receptor anta...\n",
       "430         HTR3A       antagonist                                                  Warning And Precaution  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Serotonin syndrome : Reported with 5-HT3 recep...\n",
       "431         HTR3A       antagonist                                                  Warning And Precaution  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... syndrome has been reported with 5-HT3 rece...\n",
       "432         HTR3A       antagonist                                                  Warning And Precaution  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... of serotonin syndrome related to 5-HT3 rec...\n",
       "433         HTR3A          blocker                                                             Description  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... of ondansetron and a selective blocking ag...\n",
       "434  LOC107987479        deficient                                                   Clinical Pharmacology  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... one enzyme (e.g., CYP2D6 genetic deficienc...\n",
       "435  LOC107987479        deficient                                                           Other Section  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... one enzyme (e.g., CYP2D6 genetic deficienc...\n",
       "436                                    10028997             Neoplasm malignant         Indications & Usage  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  highly emetogenic cancer chemotherapy, includi...\n",
       "437                                    10028997             Neoplasm malignant         Indications & Usage  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... repeat courses of moderately emetogenic ca...\n",
       "438                                    10028997             Neoplasm malignant         Indications & Usage  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... vomiting associated with highly emetogenic...\n",
       "439                                    10028997             Neoplasm malignant         Indications & Usage  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... repeat courses of moderately emetogenic ca...\n",
       "440                                    10047700                       Vomiting         Indications & Usage  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... indicated for the prevention of nausea and...\n",
       "441                                    10047700                       Vomiting         Indications & Usage  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  nausea and vomiting associated with highly eme...\n",
       "442                                    10047700                       Vomiting         Indications & Usage  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  nausea and vomiting associated with initial an...\n",
       "443                                    10047700                       Vomiting         Indications & Usage  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  nausea and vomiting associated with radiothera...\n",
       "444                                    10066962              Procedural nausea         Indications & Usage  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... indicated for the prevention of postoperat...\n",
       "445                                    10066962              Procedural nausea         Indications & Usage  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...              postoperative nausea and/or vomiting.\n",
       "446                                    10066963            Procedural vomiting         Indications & Usage  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...          ... postoperative nausea and/or vomiting.\n",
       "447                                    10066963            Procedural vomiting         Indications & Usage  ANDA076183            20200406  https://dailymed.nlm.nih.gov/dailymed/lookup.c...              postoperative nausea and/or vomiting.\n",
       "448        CYP2D6        deficient                                                   Clinical Pharmacology  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... one enzyme (e.g., CYP2D6 genetic deficienc...\n",
       "449        CYP2D6        deficient                                                           Other Section  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... one enzyme (e.g., CYP2D6 genetic deficienc...\n",
       "450        CYP2D7        deficient                                                   Clinical Pharmacology  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... one enzyme (e.g., CYP2D6 genetic deficienc...\n",
       "451        CYP2D7        deficient                                                           Other Section  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... one enzyme (e.g., CYP2D6 genetic deficienc...\n",
       "452        CYP3A4          inducer                                                   Clinical Pharmacology  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  CYP 3A4 Inducers: Ondansetron elimination may ...\n",
       "453        CYP3A4          inducer                                                   Clinical Pharmacology  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... epileptic patients maintained chronically ...\n",
       "454        CYP3A4          inducer                                                        Drug Interaction  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  In patients treated with potent inducers of CY...\n",
       "455        CYP3A4          inducer                                                           Other Section  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  In patients treated with potent inducers of CY...\n",
       "456        CYP3A4          inducer                                                           Other Section  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  CYP 3A4 Inducers: Ondansetron elimination may ...\n",
       "457        CYP3A4          inducer                                                           Other Section  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... epileptic patients maintained chronically ...\n",
       "458        CYP4F3          inducer                                                   Clinical Pharmacology  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... elimination may be affected by cytochrome ...\n",
       "459        CYP4F3          inducer                                                           Other Section  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... elimination may be affected by cytochrome ...\n",
       "460        CYP4F3        inhibitor                                                        Drug Interaction  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... itself appear to induce or inhibit the cyt...\n",
       "461        CYP4F3        inhibitor                                                           Other Section  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... itself appear to induce or inhibit the cyt...\n",
       "462         HTR3A       antagonist     10020751               Hypersensitivity               Other Section  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... in patients who have exhibited hypersensit...\n",
       "463         HTR3A       antagonist     10020751               Hypersensitivity      Warning And Precaution  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... in patients who have exhibited hypersensit...\n",
       "464         HTR3A       antagonist     10040108             Serotonin syndrome               Other Section  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  The majority of reports of serotonin syndrome ...\n",
       "465         HTR3A       antagonist     10040108             Serotonin syndrome      Warning And Precaution  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  The majority of reports of serotonin syndrome ...\n",
       "466         HTR3A       antagonist                                                   Clinical Pharmacology  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Ondansetron is a selective 5-HT3 receptor anta...\n",
       "467         HTR3A       antagonist                                                        Drug Interaction  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... following the concomitant use of 5-HT3 rec...\n",
       "468         HTR3A       antagonist                                                     Indications & Usage  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Ondansetron tablets are 5-HT3 receptor antagon...\n",
       "469         HTR3A       antagonist                                                           Other Section  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... syndrome has been reported with 5-HT3 rece...\n",
       "470         HTR3A       antagonist                                                           Other Section  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... of serotonin syndrome related to 5-HT3 rec...\n",
       "471         HTR3A       antagonist                                                           Other Section  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... following the concomitant use of 5-HT3 rec...\n",
       "472         HTR3A       antagonist                                                           Other Section  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Ondansetron is a selective 5-HT3 receptor anta...\n",
       "473         HTR3A       antagonist                                                  Warning And Precaution  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  Serotonin Syndrome : Reported with 5-HT3 recep...\n",
       "474         HTR3A       antagonist                                                  Warning And Precaution  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... syndrome has been reported with 5-HT3 rece...\n",
       "475         HTR3A       antagonist                                                  Warning And Precaution  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... of serotonin syndrome related to 5-HT3 rec...\n",
       "476         HTR3A          blocker                                                             Description  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... of ondansetron and a selective blocking ag...\n",
       "477  LOC107987479        deficient                                                   Clinical Pharmacology  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... one enzyme (e.g., CYP2D6 genetic deficienc...\n",
       "478  LOC107987479        deficient                                                           Other Section  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... one enzyme (e.g., CYP2D6 genetic deficienc...\n",
       "479                                    10028997             Neoplasm malignant         Indications & Usage  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  highly emetogenic cancer chemotherapy, includi...\n",
       "480                                    10028997             Neoplasm malignant         Indications & Usage  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... repeat courses of moderately emetogenic ca...\n",
       "481                                    10028997             Neoplasm malignant         Indications & Usage  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... vomiting associated with highly emetogenic...\n",
       "482                                    10028997             Neoplasm malignant         Indications & Usage  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... repeat courses of moderately emetogenic ca...\n",
       "483                                    10047700                       Vomiting         Indications & Usage  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... indicated for the prevention of nausea and...\n",
       "484                                    10047700                       Vomiting         Indications & Usage  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  nausea and vomiting associated with highly eme...\n",
       "485                                    10047700                       Vomiting         Indications & Usage  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  nausea and vomiting associated with initial an...\n",
       "486                                    10047700                       Vomiting         Indications & Usage  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  nausea and vomiting associated with radiothera...\n",
       "487                                    10066962              Procedural nausea         Indications & Usage  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...  ... indicated for the prevention of postoperat...\n",
       "488                                    10066962              Procedural nausea         Indications & Usage  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...          postoperative nausea and/or vomiting (...\n",
       "489                                    10066963            Procedural vomiting         Indications & Usage  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...          ... postoperative nausea and/or vomiting.\n",
       "490                                    10066963            Procedural vomiting         Indications & Usage  ANDA076183            20211124  https://dailymed.nlm.nih.gov/dailymed/lookup.c...           postoperative nausea and/or vomiting (1)"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "\n",
    "# initiate an empty dataframe\n",
    "df = pd.DataFrame()\n",
    "pd.set_option(\"display.max_rows\", None, \"display.max_columns\", None, \"display.width\", 1000)\n",
    "\n",
    "# Retrieve main results from the JSON response, please note this cell would fail if the request failed in the last step\n",
    "for results in results_json:\n",
    "    for result_dict in results:\n",
    "        df_dict = {}\n",
    "        for key, value in result_dict.items():\n",
    "            df_dict[key] = value\n",
    "        df = pd.concat([df, pd.DataFrame.from_records([{**df_dict}])], ignore_index=True)\n",
    "\n",
    "# Check the dataframe\n",
    "df"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "264856f7",
   "metadata": {},
   "source": [
    "### Optional: Make a request to openFDA drug product labeling API to get FDAIDs associated with a specific criteria\n",
    "\n",
    "Search URL for the openFDA drug product labeling API that allows user to search for the FDAId's of 10 documents. Search can be customized by modifying the search parameters. In this example, the search will return 10 FDAIds of FDA Drug Labels about prescription drugs with indications and usage for cancer.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "c6aaf6df",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "No openFDA application number found for response results id: 8cdcf814-f5ee-43b6-bf09-68eab5e5befe\n",
      "['NDA204114', 'ANDA075798', 'ANDA040584', 'NDA050629', 'ANDA204345', 'NDA021116', 'NDA022234', 'ANDA080352', 'ANDA211495']\n"
     ]
    }
   ],
   "source": [
    "import json\n",
    "\n",
    "# Search URL for the openFDA drug product labeling API\n",
    "# Search can be customized by modifying the search parameters in the URL\n",
    "\n",
    "url = \"https://api.fda.gov/drug/label.json?search=openfda.product_type:prescription+AND+indications_and_usage:'cancer'&limit=10\"\n",
    "\n",
    "# load in JSON reponse from the openFDA API\n",
    "response = requests.get(url)\n",
    "body = json.loads(response.text)\n",
    "\n",
    "# initialize list for FDAID\n",
    "fdaids = []\n",
    "\n",
    "# find the openfda application number in response (if exists) and add to FDAID list\n",
    "for i in body['results']:\n",
    "    try:\n",
    "        #extract the document id (ANDA, ANADA, BA, BLA, BN, BP, DMF,K, MIF, NDA, NADA, P or VM)\n",
    "        x = i[\"openfda\"]\n",
    "        fdaids.append(x['application_number'][0])\n",
    "    except KeyError:\n",
    "        print(f\"No openFDA application number found for response results id: {i['id']}\")\n",
    "        continue\n",
    "\n",
    "print(fdaids)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "c2b66d4b",
   "metadata": {},
   "source": [
    "That's it! Hope you find this tutorial useful! Bye!"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "9b5a2363",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.10"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}